{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":129,"total_is_capped":false,"direct_labels_cover":0,"predictions_cover":129,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"query_hash":"929586e20008","filters":{"venue":"Blood Cancer Journal"}},"results":[{"id":"W2923666301","doi":"10.1038/s41408-019-0196-6","title":"Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study","year":2019,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":213,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Kite Pharma; National Institute for Health and Care Research; National Institutes of Health; American Society of Hematology; Cancer Research UK; National Cancer Institute; University College London; Celgene; University College London Hospitals NHS Foundation Trust; Sanofi; GlaxoSmithKline; Amgen; Bristol-Myers Squibb","keywords":"Medicine; Tolerability; Internal medicine; Refractory (planetary science); Multiple myeloma; Interim analysis; Lenalidomide; Transplantation; Phases of clinical research; Clinical trial; Oncology; Gastroenterology; Surgery; Adverse effect; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.02122107329605373,"gpt":0.3503603800385909,"spread":0.3291393067425372,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005277405,0.0003380826,0.0006537765,0.0003128974,0.0002020097,0.00008865875,0.000174498,0.00009896996,0.0007309141],"category_scores_gemma":[0.0001162264,0.0002562445,0.00009609563,0.0002110087,0.00006195488,0.0002863882,0.00007439138,0.0009679032,0.00007181878],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001936236,"about_ca_system_score_gemma":0.000330829,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001238323,"about_ca_topic_score_gemma":0.0005033737,"domain_scores_codex":[0.9971724,0.0003538014,0.0005850344,0.000593145,0.000734115,0.0005614877],"domain_scores_gemma":[0.9982393,0.0002359313,0.0002137534,0.0004917064,0.0001303813,0.0006889121],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02168485,0.01526343,0.8520634,0.00003520083,0.0006778422,0.002892285,0.001797475,0.00008845536,0.03872325,0.000002273555,0.00008636704,0.06668517],"study_design_scores_gemma":[0.1447652,0.00506332,0.8435265,0.0005252701,0.0002396646,0.0001082062,0.0009312716,0.0008136119,0.002669542,0.00001334619,0.001062943,0.0002811598],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957554,0.001952897,0.000006100634,0.0002757844,0.000329024,0.00129659,0.0001503141,0.00003677527,0.0001971225],"genre_scores_gemma":[0.9968053,0.00195826,0.0002296502,0.0002150479,0.0003668877,0.00002278464,0.0001525152,0.0000544095,0.0001952176],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1230803,"threshold_uncertainty_score":0.999989,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4366822278","doi":"10.1038/s41408-023-00823-9","title":"Management of chronic myeloid leukemia in 2023 – common ground and common sense","year":2023,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":172,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bosutinib; Dasatinib; Nilotinib; Ponatinib; Medicine; Imatinib; Oncology; Imatinib mesylate; Internal medicine; Myeloid leukemia; Intensive care medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.04700418793668781,"gpt":0.3555606265684206,"spread":0.3085564386317328,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005946244,0.0006285968,0.002934435,0.000561639,0.0001011462,0.00004978041,0.0002358786,0.0003660785,0.0002021045],"category_scores_gemma":[0.00001008449,0.0005152506,0.0004624184,0.0007371962,0.0001277735,0.00008481888,0.0002609763,0.001472123,0.0000463412],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.009049076,"about_ca_system_score_gemma":0.002934189,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001547206,"about_ca_topic_score_gemma":0.001101683,"domain_scores_codex":[0.9965308,0.0002156597,0.001473409,0.0005083174,0.0006344736,0.0006372989],"domain_scores_gemma":[0.9979796,0.0001587137,0.0009320317,0.0005801506,0.00005467773,0.000294789],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00005483382,0.0001631302,0.0003258849,0.05667026,0.003736373,0.008883324,0.00006771093,0.00001332383,0.000001639298,0.00003486424,0.0008256052,0.9292231],"study_design_scores_gemma":[0.01431398,0.0007614488,0.00295649,0.2564664,0.0177066,0.01208324,0.0001432029,0.00005377881,0.00001062533,0.0001262948,0.6945491,0.0008289149],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.009163806,0.9879308,7.121739e-7,0.00004899655,0.0005313035,0.00118647,0.00009092603,0.00003590191,0.001011121],"genre_scores_gemma":[0.0003936514,0.9957544,0.00008416923,0.00002741769,0.0006702226,0.0001663176,0.00008002282,0.000145618,0.002678168],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9283941,"threshold_uncertainty_score":0.9997299,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3083502363","doi":"10.1038/s41408-020-00357-4","title":"Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study","year":2020,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":153,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; Dalhousie University","funders":"AbbVie Biotherapeutics; Bristol-Myers Squibb","keywords":"Lenalidomide; Medicine; Dexamethasone; Internal medicine; Multiple myeloma; Regimen; Hazard ratio; Clinical endpoint; Oncology; Adverse effect; Randomized controlled trial; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.1002394415893604,"gpt":0.3762224000222738,"spread":0.2759829584329133,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001453645,0.0002519347,0.0008650795,0.00007878869,0.0001780157,0.0001303762,0.0001860455,0.00006084463,0.0003722535],"category_scores_gemma":[0.001419674,0.0001487032,0.0001696881,0.0002141652,0.0001252944,0.0001160342,0.00008979256,0.000811171,0.00001005785],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001030146,"about_ca_system_score_gemma":0.0004695335,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004713737,"about_ca_topic_score_gemma":0.0006499786,"domain_scores_codex":[0.996747,0.0009383159,0.0007028774,0.0004007705,0.000760844,0.0004501704],"domain_scores_gemma":[0.9977677,0.001117358,0.000231736,0.0002333127,0.0001175934,0.0005322321],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8065581,0.003736213,0.1342194,0.00003015385,0.004291557,0.005704218,0.008488241,0.00003014292,0.001444546,0.0000270666,0.001706981,0.03376332],"study_design_scores_gemma":[0.9235181,0.001270096,0.07107956,0.0001851091,0.0008425472,0.0001350188,0.001102511,0.0005380003,0.0004355516,0.0001098615,0.0006153675,0.0001682316],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9839635,0.005628549,0.00003911597,0.008340861,0.0001462487,0.001341982,0.0001304395,0.00001922063,0.0003900517],"genre_scores_gemma":[0.995623,0.002309217,0.0003323585,0.0006456617,0.0007826367,0.00009530854,0.0000234752,0.0000270303,0.0001613138],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.11696,"threshold_uncertainty_score":0.7125791,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2778096288","doi":"10.1038/s41408-017-0035-6","title":"Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients","year":2017,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":147,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"University of Calgary; Mayo Clinic","keywords":"Medicine; Venous thrombosis; Internal medicine; Thrombosis; Polycythemia vera; Cardiology","retraction":null,"screen_n_in":null,"score":{"opus":0.0634775556548781,"gpt":0.348447804704172,"spread":0.2849702490492939,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000805849,0.0001923587,0.0003873873,0.00009636054,0.0002966059,0.0001143472,0.0001384423,0.00007828398,0.0001360766],"category_scores_gemma":[0.0001998235,0.0001490807,0.0001162352,0.0000432312,0.00005615112,0.0001919727,0.00003440877,0.0002268604,0.00000244502],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003586142,"about_ca_system_score_gemma":0.0001341856,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006030662,"about_ca_topic_score_gemma":0.001117615,"domain_scores_codex":[0.998781,0.00003486436,0.0003239334,0.0002499046,0.0002396159,0.0003707131],"domain_scores_gemma":[0.9991664,0.00007537937,0.0002958482,0.0002273425,0.00008164837,0.0001533966],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00140158,0.002742475,0.9878214,0.00001206548,0.0001622209,0.00003636709,0.00367462,0.000004368399,0.0005120655,0.00000325776,0.0001322607,0.003497295],"study_design_scores_gemma":[0.03206747,0.00208523,0.9521943,0.0003294395,0.0001552982,0.00001290352,0.0003106816,0.0000126078,0.01174969,0.0000201821,0.0009003228,0.0001619192],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9972267,0.0001646301,0.000004464627,0.000251325,0.001510476,0.0005540786,0.0001015182,0.000006185768,0.0001805942],"genre_scores_gemma":[0.9985709,0.000511464,0.0001640118,0.00005441709,0.0004202968,0.0002324022,0.00001085594,0.00002174609,0.00001387746],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03562716,"threshold_uncertainty_score":0.6079333,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2771668512","doi":"10.1038/s41408-017-0023-x","title":"CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment","year":2017,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Hospital for Sick Children","funders":"Amgen","keywords":"Blinatumomab; Lymphoblastic Leukemia; Medicine; CD19; Oncology; Acute lymphocytic leukemia; Internal medicine; Leukemia; Peripheral blood","retraction":null,"screen_n_in":null,"score":{"opus":0.02060519759819452,"gpt":0.304392714943682,"spread":0.2837875173454875,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0004970841,0.001141591,0.002284747,0.001070269,0.0005758156,0.0002296273,0.001167727,0.001547155,0.0003972297],"category_scores_gemma":[0.0005408184,0.0008870197,0.001574652,0.0004413857,0.0002843427,0.0003257681,0.0002627535,0.003959315,0.0001129701],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.008864621,"about_ca_system_score_gemma":0.02190807,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004576979,"about_ca_topic_score_gemma":0.00002238479,"domain_scores_codex":[0.9931279,0.0003075291,0.001415751,0.001036562,0.002512946,0.001599292],"domain_scores_gemma":[0.9940845,0.0008522269,0.002232693,0.001404727,0.0007802699,0.0006456061],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001036795,0.0006133314,0.002272632,0.001072543,0.008245389,0.05139416,0.0007342422,0.00002782401,0.0007695204,9.849404e-7,0.932065,0.001767545],"study_design_scores_gemma":[0.2733552,0.02702219,0.003752801,0.01198216,0.1936893,0.03485044,0.0004486734,0.001232928,0.0681336,0.0007863865,0.3782358,0.006510522],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7142226,0.04057791,0.0003636134,0.2035864,0.01441148,0.006279705,0.002187239,0.000353124,0.01801796],"genre_scores_gemma":[0.3629694,0.07882334,0.01012486,0.1082189,0.1642715,0.001819178,0.000826263,0.002628746,0.2703179],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5538293,"threshold_uncertainty_score":0.9997491,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4391482982","doi":"10.1038/s41408-023-00966-9","title":"GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review","year":2024,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Janssen Research and Development","keywords":"Medicine; Multiple myeloma; Chimeric antigen receptor; Clinical trial; Adverse effect; Pharmacodynamics; Malignancy; Cytokine release syndrome; Immunotherapy; Oncology; Antigen; Internal medicine; Pharmacokinetics; Immunology; Immune system","retraction":null,"screen_n_in":null,"score":{"opus":0.1028294294267789,"gpt":0.4423208833592079,"spread":0.339491453932429,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003678451,0.0006285414,0.002725101,0.0002102364,0.0002439833,0.00005564879,0.0002730764,0.0001770724,0.0004105895],"category_scores_gemma":[0.000284605,0.0002835387,0.002121454,0.0004240643,0.0001079798,0.00004983749,0.00003940053,0.0005503907,0.00004056393],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005604199,"about_ca_system_score_gemma":0.003166091,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001239798,"about_ca_topic_score_gemma":0.00004604613,"domain_scores_codex":[0.9972479,0.0001175282,0.00101027,0.0004427672,0.0006345751,0.0005469808],"domain_scores_gemma":[0.9976019,0.0005389023,0.0006168,0.0004812877,0.0003826179,0.0003785171],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001707183,0.001303477,0.0000151336,0.05911493,0.01337934,0.0002989864,0.0003906662,2.688844e-7,0.000003343152,0.00001266607,0.007810505,0.9175],"study_design_scores_gemma":[0.004332084,0.002574465,0.000004655225,0.1022958,0.02367442,0.002267899,0.00006244255,0.00001481642,0.0000235928,0.00001586631,0.8645443,0.0001897011],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00001050158,0.9920326,0.0000379109,0.0008708197,0.0005116437,0.005485606,0.000873187,0.00002000931,0.0001576984],"genre_scores_gemma":[0.00001408863,0.9906043,0.0009579505,0.00009301802,0.001307608,0.00343888,0.0001160468,0.0001017393,0.003366415],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9173102,"threshold_uncertainty_score":0.9999617,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2807346792","doi":"10.1038/s41408-018-0087-2","title":"Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia","year":2018,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network; McGill University; McGill University Health Centre","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research","keywords":"Myeloid leukemia; Stem cell; Leukemia; Myeloid; Haematopoiesis; Cancer research; Medicine; Pharmacology; Oncology; Biology; Immunology; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.02751175451481348,"gpt":0.325757277402375,"spread":0.2982455228875615,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0009141611,0.0004406151,0.0005954828,0.0003540455,0.0006361391,0.0002514671,0.0006708372,0.0003787052,0.0007705557],"category_scores_gemma":[0.00002765955,0.0003569495,0.0003099818,0.00058992,0.0003193839,0.0003267814,0.0002077148,0.002526582,0.0001509808],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001936983,"about_ca_system_score_gemma":0.003941911,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001264265,"about_ca_topic_score_gemma":0.00001924689,"domain_scores_codex":[0.9962194,0.0001180422,0.0007501249,0.0005403933,0.001215162,0.001156901],"domain_scores_gemma":[0.9974644,0.0001129542,0.0004324669,0.0004940744,0.0009215481,0.0005745845],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0006063955,0.0002154563,0.003152302,0.0001062198,0.001366223,0.000437776,0.001171788,0.00004591461,0.9518567,0.00002346191,0.02793569,0.01308206],"study_design_scores_gemma":[0.0185224,0.002038348,0.009822113,0.0007266247,0.003189176,0.004479608,0.001135708,0.002660288,0.8669276,0.0001440803,0.08928877,0.001065271],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.980563,0.01164953,0.001564997,0.001433362,0.00133587,0.0004479018,0.00004864122,0.0001280168,0.002828627],"genre_scores_gemma":[0.9714229,0.005853193,0.00439021,0.003478269,0.007038149,0.00003425716,0.00001448805,0.0001671676,0.007601401],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0849291,"threshold_uncertainty_score":0.9998882,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3168326299","doi":"10.1038/s41408-021-00507-2","title":"KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma","year":2021,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Celgene; bluebird bio; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Multiple myeloma; Refractory (planetary science); Oncology; Surgery","retraction":null,"screen_n_in":null,"score":{"opus":0.03656334346597759,"gpt":0.3583077447515886,"spread":0.321744401285611,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002115878,0.0001937208,0.0006717534,0.0002560213,0.00009736461,0.00003143166,0.00008159413,0.00006583794,0.0002212913],"category_scores_gemma":[0.0001442908,0.0001395333,0.00008522115,0.0003510096,0.00008919107,0.0000924144,0.0000517582,0.0005275256,0.000002851107],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001523605,"about_ca_system_score_gemma":0.0006049516,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009567635,"about_ca_topic_score_gemma":0.008316752,"domain_scores_codex":[0.9981499,0.0001208457,0.0005089692,0.0002680207,0.0005674005,0.0003848179],"domain_scores_gemma":[0.9987122,0.0001810059,0.0002294397,0.0002569735,0.0002514175,0.0003689142],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001055117,0.001149537,0.963268,0.00009685605,0.0006124,0.001561552,0.0004720587,0.0000257563,0.0175281,0.000007221895,0.0001628806,0.01406051],"study_design_scores_gemma":[0.01768631,0.0005745741,0.9354808,0.0004558593,0.0002106275,0.0002711916,0.0004355049,0.0001818817,0.04403504,0.00001543365,0.0005212486,0.0001314877],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9936924,0.004243417,0.00000852203,0.0007743512,0.00008255966,0.0002198895,0.00002438273,0.00001406918,0.0009403945],"genre_scores_gemma":[0.9947786,0.00165893,0.002099173,0.00008966745,0.0001002816,0.00002432204,0.00001051189,0.0000303965,0.001208088],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02778717,"threshold_uncertainty_score":0.5690003,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2417787511","doi":"10.1038/bcj.2016.36","title":"Transcriptome analysis of G protein-coupled receptors in distinct genetic subgroups of acute myeloid leukemia: identification of potential disease-specific targets","year":2016,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Chemokine receptors and signaling","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Fonds de Recherche du Québec - Santé; Deutsche Krebshilfe; Université de Montréal; Government of Canada; Génome Québec; Compute Canada; Genome Canada","keywords":"Chemokine receptor; CX3CR1; Myeloid leukemia; Receptor; G protein-coupled receptor; Biology; CXCR4; Leukemia; Immunology; Myeloid; Cancer research; Chemokine; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.01087940075883715,"gpt":0.2460129510290285,"spread":0.2351335502701914,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000396126,0.0001752025,0.0007403187,0.0005923909,0.00003811445,0.000009881937,0.0001693942,0.00008653945,0.0009048205],"category_scores_gemma":[0.00003386148,0.000124814,0.0004975975,0.000864278,0.0001240837,0.00009719055,0.00001648934,0.0001836133,6.170847e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001992174,"about_ca_system_score_gemma":0.0003367458,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008716402,"about_ca_topic_score_gemma":0.00002397146,"domain_scores_codex":[0.9975923,0.00006890226,0.001239917,0.0002540362,0.0005971542,0.0002476701],"domain_scores_gemma":[0.9983735,0.00002546883,0.0007998993,0.0002518775,0.0003587187,0.0001904987],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0007458032,0.0002543056,0.120543,0.0001224879,0.001764348,0.00002703961,0.0002140224,0.0001720731,0.8719826,0.000006733276,0.0000264006,0.004141273],"study_design_scores_gemma":[0.004097546,0.0001730159,0.408108,0.0006111666,0.005805746,0.00002305855,0.0000572262,0.0004981423,0.5803185,0.00006244847,0.00007889616,0.0001662381],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9897439,0.00511645,0.004298659,0.0002122624,0.0002133359,0.0002898134,0.0001124564,0.000006970789,0.000006106012],"genre_scores_gemma":[0.996366,0.002949778,0.0002830898,0.000004550286,0.0002186752,0.00002289239,0.00001828713,0.00002421362,0.0001125143],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2916641,"threshold_uncertainty_score":0.990715,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2045832601","doi":"10.1038/bcj.2013.24","title":"BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia","year":2013,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":85,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Leukaemia and Lymphoma Research; Cancer Research UK; Genome Canada; Wellcome Trust; GlaxoSmithKline; Ontario Ministry of Research and Innovation; Pfizer; Eli Lilly and Company","keywords":"Bromodomain; Downregulation and upregulation; BET inhibitor; Cancer research; Dexamethasone; BRD4; Cytotoxic T cell; Cell cycle checkpoint; Medicine; In vitro; Cell cycle; Biology; Immunology; Epigenetics; Gene; Internal medicine; Genetics; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.01032834145084928,"gpt":0.2323381175858695,"spread":0.2220097761350202,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001593325,0.0001914495,0.0001908501,0.000125753,0.00009951163,0.0001099409,0.0001629104,0.000172095,0.0002015465],"category_scores_gemma":[0.00003222308,0.0001522903,0.00009730071,0.0002364588,0.00005134531,0.00002859542,0.00006327317,0.0002178398,0.00002501638],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001082744,"about_ca_system_score_gemma":0.0004317093,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003465743,"about_ca_topic_score_gemma":0.00001214863,"domain_scores_codex":[0.9987281,0.0001094717,0.0003491818,0.0002684408,0.0002237544,0.0003210565],"domain_scores_gemma":[0.9993681,0.00001202831,0.0001928056,0.000173356,0.0001113226,0.0001423727],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0005543592,0.0009035571,0.005700045,0.00006037189,0.0002817371,0.0000295852,0.0001291516,0.00009243438,0.963439,0.00002937732,0.008990292,0.01979011],"study_design_scores_gemma":[0.01903828,0.004314403,0.02176315,0.0002467911,0.0004837801,0.001681021,0.0002605453,0.000377996,0.9412185,0.001184564,0.008154718,0.001276277],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9943311,0.002770124,0.0006073702,0.0003534364,0.0002687014,0.000388489,0.00001161982,0.00001532764,0.001253829],"genre_scores_gemma":[0.9953861,0.001080805,0.0006899622,0.001165924,0.0006259116,0.0001201956,0.00007072067,0.00003213629,0.0008282355],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02222051,"threshold_uncertainty_score":0.6210219,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4200418432","doi":"10.1038/s41408-021-00584-3","title":"Differentiation therapy for myeloid malignancies: beyond cytotoxicity","year":2021,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; Leukemia & Lymphoma Society of Canada; Canada's Michael Smith Genome Sciences Centre","funders":"BC Cancer Foundation; University of British Columbia; Genome British Columbia; Leukemia and Lymphoma Society of Canada; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Leukemia and Lymphoma Society; Genome Canada; Terry Fox Research Institute","keywords":"Myeloid leukemia; Myeloid; Azacitidine; Medicine; Differentiation therapy; Acute promyelocytic leukemia; Myelodysplastic syndromes; Immunology; Haematopoiesis; Cancer research; Stem cell; Biology; Retinoic acid; Bone marrow; DNA methylation","retraction":null,"screen_n_in":null,"score":{"opus":0.06473534785784331,"gpt":0.3828485920994154,"spread":0.3181132442415721,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007128397,0.0005870163,0.002598228,0.0003817783,0.0003263428,0.0002072848,0.0004142919,0.0005457936,0.001130566],"category_scores_gemma":[0.0002167117,0.0004204591,0.001526868,0.000499244,0.00007604506,0.0001220177,0.00009155741,0.00168981,0.00001592955],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001105646,"about_ca_system_score_gemma":0.006742927,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001844704,"about_ca_topic_score_gemma":0.000009102067,"domain_scores_codex":[0.996564,0.0002664915,0.001010964,0.0005662483,0.0008251897,0.0007671398],"domain_scores_gemma":[0.9973044,0.0002652815,0.0007443187,0.0005081855,0.0007373676,0.0004403921],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00008882082,0.0004165233,0.00004650933,0.009680831,0.002954035,0.0002139306,0.00009141261,5.605949e-7,0.0001890535,0.00005349651,0.01705351,0.9692113],"study_design_scores_gemma":[0.003816621,0.0005116935,0.00003580057,0.01751748,0.003091686,0.002625579,0.00003257924,0.000007360669,0.0004583455,0.00004050003,0.9714541,0.0004082645],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0004272413,0.9955983,0.0004582976,0.0003574579,0.0007062531,0.001981172,0.0002494031,0.00003880056,0.0001831005],"genre_scores_gemma":[0.00001554796,0.9902039,0.000901147,0.0004103624,0.004514318,0.0008098481,0.0002555732,0.0001687222,0.002720579],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.968803,"threshold_uncertainty_score":0.9998247,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2925264218","doi":"10.1038/s41408-019-0200-1","title":"Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide","year":2019,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Lenalidomide; Pomalidomide; Daratumumab; Medicine; Carfilzomib; Multiple myeloma; Intensive care medicine; Population; Clinical trial; Ixazomib; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.01894229791230373,"gpt":0.2947074009130907,"spread":0.2757651030007869,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005211445,0.0002436371,0.0004551225,0.0001429114,0.00009730189,0.00003564965,0.00007298293,0.00004854427,0.0002789306],"category_scores_gemma":[0.00000992737,0.0001238939,0.00009976784,0.0001318691,0.00006364544,0.0001027789,0.000007385771,0.0001618537,0.00001302668],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002045428,"about_ca_system_score_gemma":0.000387438,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001078618,"about_ca_topic_score_gemma":0.00004699497,"domain_scores_codex":[0.9983416,0.00005241993,0.0002535091,0.0002480626,0.0007154908,0.0003889473],"domain_scores_gemma":[0.9988592,0.00005328453,0.0002404438,0.0002608816,0.0003019842,0.0002841995],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01865733,0.003106871,0.8817666,0.00003248636,0.001363882,0.0001944327,0.0001954701,0.00004199845,0.0006135198,0.0000012054,0.00002532415,0.09400091],"study_design_scores_gemma":[0.0897256,0.02260601,0.8580751,0.0006075067,0.0002197797,0.0001278631,0.00005598083,0.00008443832,0.02663291,0.000002273189,0.001701101,0.000161419],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9967177,0.001621998,0.00001126545,0.0002059754,0.00007037598,0.001022434,0.00003849324,0.00001734623,0.0002944337],"genre_scores_gemma":[0.9968055,0.0005728981,0.001816097,0.00004818209,0.0001852295,0.00007163123,0.0000249793,0.00004522894,0.0004301849],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0938395,"threshold_uncertainty_score":0.5052246,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4313545228","doi":"10.1038/s41408-022-00779-2","title":"The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review","year":2023,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Impact; Ottawa Hospital; McMaster University","funders":"National Institute on Aging; National Cancer Institute; Hamilton Health Sciences Foundation; Cancer Research UK; Hamilton Health Sciences","keywords":"Medicine; Clinical trial; Population; Randomized controlled trial; Frailty syndrome; Multiple myeloma; Psychological intervention; Gerontology; MEDLINE; Internal medicine; Frailty Index","retraction":null,"screen_n_in":null,"score":{"opus":0.193990178012197,"gpt":0.4970273322898045,"spread":0.3030371542776076,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01781941,0.0004150925,0.008143899,0.0003236656,0.00008030222,0.00004464582,0.000369555,0.0002516518,0.00004555345],"category_scores_gemma":[0.03227523,0.0001952932,0.001184688,0.0005444548,0.0001261462,0.00006011491,0.0001206161,0.001339729,0.00001483317],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001565493,"about_ca_system_score_gemma":0.001184446,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001128882,"about_ca_topic_score_gemma":0.0004250934,"domain_scores_codex":[0.9877411,0.004851379,0.00570009,0.0004126519,0.0008006751,0.0004940892],"domain_scores_gemma":[0.9860284,0.01046955,0.00245843,0.0005463484,0.0001768848,0.0003204239],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.00007388552,0.0002719852,0.02931353,0.7707782,0.001488247,0.0003720619,0.00003868036,1.566782e-8,1.232867e-8,0.00000103241,0.0001213688,0.1975409],"study_design_scores_gemma":[0.006816919,0.0001683652,0.02993012,0.9532375,0.00703031,0.0003604283,0.00002637007,0.000006128314,1.355979e-7,0.000004861085,0.002266748,0.0001520921],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0008438136,0.9913276,4.016144e-7,0.0002369842,0.000229804,0.007248525,0.00009364101,0.000009924113,0.000009303258],"genre_scores_gemma":[0.0002224368,0.9975991,0.00003370311,0.00005044595,0.0001630805,0.00139135,0.00000682876,0.0000505981,0.0004824403],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.1973888,"threshold_uncertainty_score":0.9758763,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4402493149","doi":"10.1038/s41408-024-01139-y","title":"Bispecific antibodies in the treatment of multiple myeloma","year":2024,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Antibody; Medicine; Hematology; Immunology; Internal medicine; Oncology; Cancer research","retraction":null,"screen_n_in":null,"score":{"opus":0.1238345304032211,"gpt":0.4311017220673892,"spread":0.3072671916641681,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002999033,0.0003760251,0.001598275,0.0004352244,0.00008988556,0.00006346939,0.0002773473,0.0001531679,0.0002557438],"category_scores_gemma":[0.00002160679,0.0001648315,0.0009857428,0.0004837838,0.0001348798,0.00002997621,0.0000325182,0.0007702913,0.00005257484],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000162516,"about_ca_system_score_gemma":0.0008301492,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002143034,"about_ca_topic_score_gemma":0.0001565303,"domain_scores_codex":[0.9977918,0.0001842579,0.0007668299,0.0002618603,0.0006078707,0.0003873943],"domain_scores_gemma":[0.9990555,0.000243704,0.0002226879,0.0002669549,0.00008745934,0.0001237092],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0000753522,0.000670113,0.0009381689,0.01172092,0.001393419,0.001881826,0.0006235126,2.521156e-7,0.000006314485,0.00004761262,0.003339797,0.9793027],"study_design_scores_gemma":[0.00069666,0.0007466167,0.000337722,0.01825547,0.002905918,0.003147269,0.00009620552,0.000002631876,0.00001693517,0.00002670951,0.9736223,0.0001455994],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00192831,0.9953723,2.824321e-7,0.0005101478,0.0004541191,0.000606313,0.0001573993,0.000008081407,0.0009630253],"genre_scores_gemma":[0.0001799695,0.9945834,0.00005935207,0.0000293264,0.001842362,0.00009577594,0.00002692605,0.00004112901,0.003141745],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9791571,"threshold_uncertainty_score":0.6721634,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2070181143","doi":"10.1038/bcj.2013.25","title":"Modifying chemotherapy response by targeted inhibition of eukaryotic initiation factor 4A","year":2013,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":62,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Université Laval; McGill University","funders":"Canadian Institutes of Health Research; McGill University","keywords":"EIF4E; PI3K/AKT/mTOR pathway; Initiation factor; Cancer research; Biology; Translation (biology); Eukaryotic initiation factor; Signal transduction; eIF4A; Cell biology; EIF4A1; Eukaryotic translation; Messenger RNA; Genetics; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.01255225650355273,"gpt":0.2616538805580792,"spread":0.2491016240545265,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002230773,0.0001533022,0.0001615069,0.00006725315,0.00008964882,0.00004623929,0.0001310448,0.0001511462,0.0005581544],"category_scores_gemma":[0.00007425853,0.0001467137,0.00009825887,0.0001027307,0.00005189957,0.00002129048,0.00002393762,0.0001843249,0.000005284449],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005701636,"about_ca_system_score_gemma":0.0002537832,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005318835,"about_ca_topic_score_gemma":0.000004235663,"domain_scores_codex":[0.9988464,0.0001418069,0.000335715,0.0002033549,0.0002320049,0.0002407187],"domain_scores_gemma":[0.9991277,0.00002094347,0.0003115597,0.0001692667,0.0002647625,0.0001057105],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0002987398,0.00007030196,0.004073363,0.00001554015,0.0001126511,0.000001704287,0.0001106927,0.0001494795,0.9857697,0.000001063963,0.007378628,0.002018135],"study_design_scores_gemma":[0.001763132,0.0003711824,0.01025243,0.00007490778,0.0000300936,0.00003537335,0.00003733041,0.00007460744,0.9855024,0.00007643011,0.001600479,0.0001816173],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9932038,0.004262798,0.001454559,0.0005374498,0.0002612566,0.0001585021,0.00006283412,0.00001018551,0.00004862291],"genre_scores_gemma":[0.9975188,0.0007881934,0.0004540755,0.0006203614,0.0003992259,0.00003608122,0.00002913326,0.00003409772,0.0001200596],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006179063,"threshold_uncertainty_score":0.61114,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4283698909","doi":"10.1038/s41408-022-00695-5","title":"Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee","year":2022,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Saint John Regional Hospital; Dalhousie University; University of New Brunswick","funders":"National Cancer Institute; National Institutes of Health","keywords":"Multiple myeloma; Medicine; Clinical trial; Carfilzomib; Lenalidomide; Refractory (planetary science); Transplantation; Oncology; Salvage therapy; Intensive care medicine; Internal medicine; Chemotherapy; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.1564013048020916,"gpt":0.3700564653846089,"spread":0.2136551605825173,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006493866,0.0004650629,0.001594442,0.0003806246,0.0004078117,0.00003773153,0.0003888445,0.0001572983,0.0002727629],"category_scores_gemma":[0.0002727899,0.0002537756,0.0006162358,0.0003455945,0.0002827827,0.00005696198,0.0001235312,0.0009621035,0.00000104255],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005141759,"about_ca_system_score_gemma":0.001414537,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006652551,"about_ca_topic_score_gemma":0.0006679466,"domain_scores_codex":[0.9962578,0.001052894,0.001190839,0.0003072498,0.0007391231,0.0004520392],"domain_scores_gemma":[0.996027,0.001946661,0.001020495,0.0006635043,0.0001338445,0.0002085231],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001843179,0.001778617,0.007603991,0.003027384,0.001902767,0.0004026427,0.00152351,0.000003194852,0.00001338893,0.00001620714,0.0008438969,0.9827001],"study_design_scores_gemma":[0.007528993,0.001129635,0.004109029,0.005880971,0.002270893,0.001362787,0.001833268,0.00001928033,0.00004089026,0.000008032944,0.9756024,0.0002138297],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0199316,0.9759377,7.113214e-7,0.0008201522,0.0003620702,0.001749849,0.0007927147,0.00001083422,0.0003944277],"genre_scores_gemma":[0.01587448,0.9825934,0.0001574947,0.00004590779,0.0001939263,0.0004976376,0.00008775459,0.00006018966,0.000489223],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9824862,"threshold_uncertainty_score":0.9999915,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2884841488","doi":"10.1038/s41408-018-0103-6","title":"High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia","year":2018,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; Institute for Research in Immunology and Cancer; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Medical Research Council; Université de Montréal; King's College London; Cancer Research UK; Compute Canada; National Institute for Health and Care Research; Leukemia and Lymphoma Society; Genome Canada; Blood Cancer UK; McGill University; Génome Québec","keywords":"Internal medicine; Oncology; Medicine; Myeloid leukemia; Cytogenetics; Cohort; Clinical trial; HMGA2; Biology; Gene; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.03007406853425897,"gpt":0.3631047606822544,"spread":0.3330306921479954,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001451709,0.0002737501,0.0009379486,0.0004226607,0.0001238836,0.00003932061,0.0004985539,0.0003715025,0.001065639],"category_scores_gemma":[0.0004567402,0.0002010188,0.0002887042,0.0003955493,0.0003613089,0.0002579335,0.0002509253,0.001859296,0.00004443636],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000664908,"about_ca_system_score_gemma":0.002962518,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000471312,"about_ca_topic_score_gemma":0.0001550036,"domain_scores_codex":[0.9961334,0.0002548399,0.001295004,0.0004183666,0.00121954,0.0006787803],"domain_scores_gemma":[0.9977711,0.0001912275,0.0004930623,0.000463746,0.0005232795,0.0005575961],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00223722,0.0007224733,0.9295992,0.00006415074,0.0008200608,0.0009536013,0.0003808854,0.00000797776,0.03478479,0.00002033633,0.01572653,0.01468275],"study_design_scores_gemma":[0.02518163,0.002824824,0.7988568,0.001039716,0.0006358993,0.001186392,0.0001617492,0.0001184933,0.16763,0.0002096117,0.001849425,0.0003054922],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9956731,0.0005546344,0.000118442,0.001564141,0.001022731,0.0003934828,0.0000448369,0.00003335804,0.0005952831],"genre_scores_gemma":[0.9897695,0.002335227,0.003006988,0.0008906737,0.002175228,0.00002898708,0.00000721065,0.0000566806,0.001729554],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1328452,"threshold_uncertainty_score":0.9998475,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2015577159","doi":"10.1038/bcj.2012.47","title":"Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling molecules","year":2013,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University Medical Centre","funders":"Deutsche Forschungsgemeinschaft","keywords":"Biology; Receptor tyrosine kinase; Cancer research; KRAS; Somatic cell; Signal transduction; ERBB3; Germline mutation; Mutation; Multiple myeloma; Genetics; Gene; Cell biology; Immunology","retraction":null,"screen_n_in":null,"score":{"opus":0.01489273245127348,"gpt":0.275135734178183,"spread":0.2602430017269096,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001125176,0.0002195157,0.0003322095,0.000196239,0.0002166547,0.0001242567,0.00006382402,0.00008659207,0.0005192545],"category_scores_gemma":[0.0002400874,0.0001761854,0.00006114467,0.000157758,0.00008678588,0.0001724201,0.00004366512,0.0002923032,0.00001977206],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008499035,"about_ca_system_score_gemma":0.0001071468,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007889593,"about_ca_topic_score_gemma":0.0001436296,"domain_scores_codex":[0.9985074,0.0001093437,0.0003459827,0.0002842138,0.0003251561,0.0004279231],"domain_scores_gemma":[0.9989102,0.0001899096,0.0001195465,0.0001376189,0.0001340366,0.0005086383],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0001985195,0.0007057629,0.3479345,0.0001804088,0.0003727578,0.0003022974,0.0007239542,0.00002696939,0.6157781,5.359078e-7,0.0008643318,0.03291183],"study_design_scores_gemma":[0.03367476,0.001398901,0.3383443,0.001684788,0.0004126962,0.001452299,0.0005609649,0.01995839,0.6015083,0.0001566286,0.0002711586,0.0005768515],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9868274,0.01144139,0.0000587286,0.0008201751,0.00004973146,0.000690034,0.00007789639,0.00002536352,0.000009235104],"genre_scores_gemma":[0.9943208,0.001651647,0.003411699,0.0001866148,0.00009448556,0.0001698615,0.00003729857,0.00003583124,0.00009180568],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03347624,"threshold_uncertainty_score":0.7184631,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4392298224","doi":"10.1038/s41408-024-01002-0","title":"Dual T-cell constant β chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry","year":2024,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université du Québec à Montréal","funders":"Academy of Medical Sciences; Medical Research Council; National Institute for Health and Care Research; Cancer Research UK; European Hematology Association","keywords":"Flow cytometry; T cell; Staining; CD8; Cell; Antibody; Molecular biology; Biology; Antigen; Immunology; Pathology; Medicine; Immune system; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.0153692314504759,"gpt":0.3134933320987272,"spread":0.2981241006482512,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009504631,0.0001485611,0.0002593107,0.0002048915,0.0002210118,0.00016851,0.0001030949,0.00007175587,0.0001549921],"category_scores_gemma":[0.0001504429,0.0001030019,0.0001124257,0.0003270933,0.0001686603,0.00007882452,0.00003299539,0.0003693418,0.000002649867],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000105572,"about_ca_system_score_gemma":0.0007866488,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003443844,"about_ca_topic_score_gemma":0.00001721526,"domain_scores_codex":[0.9984014,0.00006528097,0.0004781373,0.0002416923,0.0004974721,0.0003160221],"domain_scores_gemma":[0.9988217,0.0004393915,0.0001452376,0.0001566435,0.0002915635,0.0001454796],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0007365782,0.0003710403,0.004292172,0.001042516,0.000611001,0.0001624667,0.003148035,0.0001092792,0.9406603,0.00009202131,0.01562857,0.03314603],"study_design_scores_gemma":[0.01382982,0.002244735,0.000400927,0.0008867125,0.001717437,0.007774884,0.01220161,0.08997346,0.8491799,0.000559649,0.02069596,0.0005348921],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8978764,0.0844645,0.01192705,0.003205491,0.0004794057,0.00103352,0.0003919195,0.00003345693,0.0005882623],"genre_scores_gemma":[0.9908713,0.005798296,0.0003321275,0.0001303748,0.0002905219,0.00007075116,0.00001239775,0.00004026361,0.002454027],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09299484,"threshold_uncertainty_score":0.4200297,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3021689191","doi":"10.1038/s41408-020-0321-6","title":"Venetoclax for the treatment of translocation (11;14) AL amyloidosis","year":2020,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Amyloidosis: Diagnosis, Treatment, Outcomes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":54,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"National Cancer Institute","keywords":"Chromosomal translocation; Venetoclax; Amyloidosis; AL amyloidosis; Medicine; Internal medicine; Oncology; Cancer research; Leukemia; Immunology; Biology; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.02581167300333707,"gpt":0.2980678110796958,"spread":0.2722561380763587,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007015306,0.0001745279,0.0002116601,0.00002042244,0.0001464157,0.00002611418,0.0001910296,0.00007619227,0.0000536426],"category_scores_gemma":[0.00002552726,0.0001178259,0.0002888017,0.00007735276,0.00005444453,0.000005091073,0.00001096414,0.00004893793,0.000001609126],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000637869,"about_ca_system_score_gemma":0.0002449535,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006726233,"about_ca_topic_score_gemma":0.0001249123,"domain_scores_codex":[0.9991022,0.00003940322,0.0002795245,0.0002190747,0.0001444069,0.0002153543],"domain_scores_gemma":[0.9993559,0.00004193963,0.0001933954,0.0001807624,0.0001086818,0.000119293],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001386952,0.00153206,0.150451,0.00009790104,0.006133357,0.00001413196,0.002814026,0.005289704,0.6198913,0.0001098116,0.03373658,0.1785432],"study_design_scores_gemma":[0.004806655,0.0022434,0.005779,0.00002477755,0.0007775471,0.00002485944,0.0001878043,0.0001283521,0.7435266,0.00001456464,0.2423041,0.0001822843],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9430174,0.03787059,0.002694315,0.01515227,0.0003679745,0.0006818383,0.0001672787,0.00001149995,0.00003679058],"genre_scores_gemma":[0.963836,0.03305813,0.0005616492,0.001335577,0.000762159,0.0003144442,0.00002471855,0.00002992541,0.00007742426],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2085676,"threshold_uncertainty_score":0.4804799,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2038656901","doi":"10.1038/bcj.2011.52","title":"Drug-mediated inhibition of Fli-1 for the treatment of leukemia","year":2012,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Health Sciences Centre; Mount Sinai Hospital; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research; Ontario Institute for Cancer Research","keywords":"Cancer research; Oncogene; Carcinogenesis; Leukemia; Transcription factor; Haematopoiesis; Drug; Biology; Cell growth; Apoptosis; Loss function; Oncogene Proteins; Gene; Medicine; Pharmacology; Regulation of gene expression; Immunology; Stem cell; Phenotype; Cell biology; Cell cycle; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.03051450591843673,"gpt":0.3259653408600217,"spread":0.295450834941585,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003903112,0.0001038938,0.0002757293,0.00009888937,0.00008275136,0.000006259104,0.00006894665,0.0000565103,0.0002314681],"category_scores_gemma":[0.00007320139,0.00005913593,0.0001745297,0.0001634552,0.00009697059,0.00008237624,0.0000113708,0.0001664421,0.000003663596],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006193019,"about_ca_system_score_gemma":0.0008636664,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002008825,"about_ca_topic_score_gemma":0.00002148275,"domain_scores_codex":[0.9989049,0.00004113877,0.0003320971,0.0000761793,0.0003318459,0.000313841],"domain_scores_gemma":[0.9989225,0.000243036,0.0002202993,0.0001697046,0.0002750245,0.0001694712],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.005151542,0.005413216,0.1617773,0.0008192628,0.005430587,0.00005833666,0.01410838,0.0001558834,0.5548627,0.0004545158,0.06907529,0.1826929],"study_design_scores_gemma":[0.02409999,0.002974088,0.0393816,0.0004076426,0.002065415,0.0005366656,0.001274845,0.0004659608,0.8628427,0.00007329816,0.06569188,0.0001858604],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9843646,0.01298906,0.0001347851,0.001371241,0.0002405782,0.0005052056,0.00005915658,0.000007496978,0.0003279381],"genre_scores_gemma":[0.9891251,0.008113925,0.0005627301,0.0001055861,0.001346971,0.00008681916,0.00001112594,0.00002202136,0.0006257314],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.30798,"threshold_uncertainty_score":0.2534414,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3132537256","doi":"10.1038/s41408-021-00429-z","title":"Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication","year":2021,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Health Sciences North","funders":"National Cancer Institute; Leukemia and Lymphoma Society","keywords":"Ibrutinib; Venetoclax; Chronic lymphocytic leukemia; Bruton's tyrosine kinase; Minimal residual disease; Medicine; Cancer research; Leukemia; Hematology; Drug development; Immunology; Oncology; Pharmacology; Drug; Internal medicine; Tyrosine kinase; Receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.02705962028518334,"gpt":0.3445483137911038,"spread":0.3174886935059205,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002526768,0.00009167493,0.0001946223,0.00006831381,0.0001470713,0.0000323466,0.00006921151,0.00005180182,0.0001630454],"category_scores_gemma":[0.000274254,0.00008440614,0.00007757408,0.0001525072,0.00007495053,0.00006344439,0.00003269326,0.0001535187,0.000001317761],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001563724,"about_ca_system_score_gemma":0.009989754,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001075216,"about_ca_topic_score_gemma":0.00003241504,"domain_scores_codex":[0.9988616,0.00005069114,0.0003436172,0.0002075766,0.0003161145,0.0002204397],"domain_scores_gemma":[0.9987497,0.0001173231,0.0001801041,0.0002400956,0.0004088376,0.0003039219],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.008754495,0.003007512,0.3396787,0.007659573,0.003274553,0.0007971023,0.002809666,0.004092031,0.4902923,0.008790012,0.07066985,0.06017419],"study_design_scores_gemma":[0.06099929,0.0007699543,0.5493747,0.001270679,0.002834584,0.002086958,0.0002845825,0.02192589,0.2973286,0.00749926,0.05500395,0.0006214987],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9868152,0.009067826,0.001081313,0.002036762,0.0001517069,0.0004595926,0.0001893303,0.00001535303,0.0001829731],"genre_scores_gemma":[0.9942569,0.0009408133,0.003254673,0.00006535317,0.0006982219,0.00008058974,0.0001177225,0.00002287531,0.0005628686],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.209696,"threshold_uncertainty_score":0.9956227,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3175478791","doi":"10.1038/s41408-021-00505-4","title":"Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients","year":2021,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Cancer Institute","keywords":"Monoclonal gammopathy of undetermined significance; Multiple myeloma; Internal medicine; Medicine; Gastroenterology; Biomarker; Cohort; Hematology; Oncology; Monoclonal; Immunology; Monoclonal antibody; Antibody; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.02987652623952529,"gpt":0.3174658281442044,"spread":0.2875893019046791,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001235636,0.0001473636,0.0003179219,0.0001272109,0.0001051153,0.00006241941,0.00005853664,0.00006059515,0.000427603],"category_scores_gemma":[0.0001560813,0.0001151175,0.00007288078,0.0001519704,0.0000313832,0.0001298135,0.0000724587,0.0003599573,0.000005101486],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001198214,"about_ca_system_score_gemma":0.0003359762,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007501402,"about_ca_topic_score_gemma":0.0001992328,"domain_scores_codex":[0.9985948,0.00006186691,0.0002802873,0.0002129207,0.0004412867,0.000408892],"domain_scores_gemma":[0.9992318,0.00004408708,0.00006945259,0.0001423362,0.0001564755,0.0003558205],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00007774375,0.0003831401,0.940128,0.00005217865,0.0003374325,0.00164412,0.0001525916,0.000002861881,0.0004948398,0.00000249164,0.00007598004,0.05664859],"study_design_scores_gemma":[0.01197112,0.0002295643,0.9815872,0.0002966593,0.00009927509,0.0004888129,0.00007738059,0.00004162412,0.004762683,0.00003728629,0.0003124171,0.00009594546],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9955742,0.002571939,0.000007430289,0.001019909,0.0001970689,0.0001798385,0.00005665435,0.00001344744,0.0003795309],"genre_scores_gemma":[0.9975945,0.0008063006,0.0004417373,0.0002112749,0.0001466016,0.00002136199,0.000006284474,0.00002067389,0.0007512193],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05655264,"threshold_uncertainty_score":0.4694354,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4376133376","doi":"10.1038/s41408-023-00843-5","title":"Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study","year":2023,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Frailty in Older Adults","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University","funders":"National Center for Advancing Translational Sciences; Agency for Healthcare Research and Quality; Hamilton Health Sciences Foundation; Hamilton Health Sciences","keywords":"Medicine; Cohort; Confidence interval; Cohort study; Population; Epidemiology; Multiple myeloma; Gerontology; Internal medicine; Demography","retraction":null,"screen_n_in":null,"score":{"opus":0.009676987236834574,"gpt":0.2988752424923265,"spread":0.2891982552554919,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006096754,0.0003491864,0.0005573367,0.0003385124,0.0004104156,0.0001060983,0.0002058897,0.0001149394,0.0004175759],"category_scores_gemma":[0.000167568,0.0002695217,0.0001513626,0.0007356157,0.00006116882,0.0002084976,0.0000443204,0.001020691,0.00002377173],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004279196,"about_ca_system_score_gemma":0.0005621171,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00284663,"about_ca_topic_score_gemma":0.01118698,"domain_scores_codex":[0.9968361,0.0001771019,0.0006030771,0.0005288199,0.001273272,0.0005815914],"domain_scores_gemma":[0.99803,0.0001731552,0.000460078,0.0005188438,0.0004119898,0.0004059367],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0002625773,0.000958468,0.98852,0.00007691247,0.0008247702,0.0005785792,0.000647418,0.002731924,0.00002806302,2.673189e-7,0.0008603767,0.004510654],"study_design_scores_gemma":[0.0191038,0.00079529,0.9530234,0.0009932236,0.001186263,0.0001332133,0.001024068,0.0233356,0.00004057429,0.000006785476,0.00004667254,0.000311139],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957272,0.0001558244,0.0003807868,0.0008181793,0.000490732,0.002006829,0.00007593237,0.0002410745,0.0001034754],"genre_scores_gemma":[0.9968114,0.0001094357,0.00137869,0.0001432689,0.0002979301,0.0004002015,0.0000981515,0.00009399887,0.0006668851],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03549662,"threshold_uncertainty_score":0.9999757,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4224221896","doi":"10.1038/s41408-022-00671-z","title":"Financial toxicity in hematological malignancies: a systematic review","year":2022,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":49,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Malignancy; Internal medicine; Intensive care medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.0827086563937685,"gpt":0.3040631644147532,"spread":0.2213545080209847,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002719397,0.0007358157,0.007987108,0.0005979477,0.0002720637,0.0001709863,0.001281289,0.0004476377,0.005861224],"category_scores_gemma":[0.001560222,0.0006884136,0.001560371,0.0008026995,0.00008302333,0.000356288,0.0002373663,0.001925857,0.0002848574],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001217487,"about_ca_system_score_gemma":0.001080926,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009649133,"about_ca_topic_score_gemma":0.0000630422,"domain_scores_codex":[0.9935573,0.0002120017,0.004382113,0.0007982794,0.0001419079,0.0009083644],"domain_scores_gemma":[0.9948013,0.0002118674,0.004074294,0.0006393555,0.00004175949,0.0002313914],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000007805329,0.000296515,0.00008037232,0.9561973,0.0003845027,0.0004119733,0.00008975428,0.000003150239,1.14791e-8,0.01759095,0.006875966,0.01806169],"study_design_scores_gemma":[0.00038391,0.0000828175,0.000005940323,0.2797798,0.0006917178,0.0009586631,0.000007875602,0.000001355859,7.941544e-8,0.002812597,0.7146087,0.0006665891],"study_design_candidate":"systematic_review","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00001840979,0.992977,0.0000362385,0.0001551847,0.001473702,0.001754639,0.0005395004,0.00003118605,0.003014146],"genre_scores_gemma":[0.00001407741,0.9955839,0.00006161007,0.001549457,0.000553437,0.001450433,0.00001774446,0.00009216321,0.0006771589],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.7077327,"threshold_uncertainty_score":0.9995567,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2081446512","doi":"10.1038/bcj.2014.71","title":"Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma","year":2014,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; Jewish General Hospital","funders":"Takeda Pharmaceuticals International; Takeda Oncology; Weill Cornell Medical College","keywords":"Medicine; Ixazomib; Follicular lymphoma; Nausea; Internal medicine; Neutropenia; Tolerability; Adverse effect; Pharmacodynamics; Gastroenterology; Lymphoma; Proteasome inhibitor; Pharmacokinetics; Pharmacology; Multiple myeloma; Toxicity; Carfilzomib","retraction":null,"screen_n_in":null,"score":{"opus":0.01404684565484182,"gpt":0.2736524728493425,"spread":0.2596056271945006,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002534996,0.0001801028,0.0003420601,0.000194792,0.00009195303,0.00002841527,0.00007290313,0.00006828802,0.0000615723],"category_scores_gemma":[0.00005101791,0.0001284452,0.0000464325,0.0002083538,0.00005055835,0.0003041739,0.0000158432,0.0001366439,0.000002317401],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002844149,"about_ca_system_score_gemma":0.0004819145,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002102274,"about_ca_topic_score_gemma":0.0001400701,"domain_scores_codex":[0.9982742,0.0001443331,0.0004805592,0.0002385684,0.0006600888,0.0002022456],"domain_scores_gemma":[0.9988695,0.00003503045,0.0003675289,0.0002071538,0.0002613754,0.00025943],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001260897,0.03615194,0.9324747,0.00002474841,0.0002008756,0.00002523763,0.000865834,0.00005856552,0.0002706682,0.00001724776,0.00007341853,0.02857586],"study_design_scores_gemma":[0.1032868,0.01447297,0.8798629,0.0003211006,0.0002941159,0.00002496739,0.0001198329,0.00007977062,0.001238545,0.00004830162,0.0001272279,0.0001234933],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.998659,0.0001400335,0.000004007082,0.0001286127,0.000136781,0.0008264788,0.00001072511,0.00001340028,0.00008101323],"genre_scores_gemma":[0.999091,0.0000176765,0.0002590664,0.0001154579,0.0003231431,0.0001257472,0.00002685712,0.00002418159,0.00001683241],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1020259,"threshold_uncertainty_score":0.5237845,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2620976364","doi":"10.1038/bcj.2017.52","title":"CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission","year":2017,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":45,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Antibody-dependent cell-mediated cytotoxicity; Interleukin-3 receptor; Transplantation; Medicine; Immunology; Haematopoiesis; Cancer research; Leukemia; Stem cell; Monoclonal antibody; Antibody; Oncology; Internal medicine; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.03181450928796736,"gpt":0.3424555418308567,"spread":0.3106410325428893,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008795724,0.0001002054,0.0002669755,0.0001523453,0.0001256773,0.00002144837,0.000104319,0.0001710572,0.0003173878],"category_scores_gemma":[0.000300401,0.00008433762,0.0000363439,0.00005697549,0.00008580909,0.0004587772,0.00003374043,0.0003878296,0.000001816341],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006609374,"about_ca_system_score_gemma":0.0001360077,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001298637,"about_ca_topic_score_gemma":0.0002376058,"domain_scores_codex":[0.9987857,0.0003734193,0.0004237044,0.0001714874,0.0001263179,0.0001194222],"domain_scores_gemma":[0.9984922,0.00006935118,0.0008979985,0.0001714998,0.0003536547,0.00001531388],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0007097716,0.0006189453,0.6818359,0.00001178696,0.00006511526,3.5645e-7,0.0001949415,0.00007682573,0.3059882,0.000002633621,0.00005229765,0.0104432],"study_design_scores_gemma":[0.007123398,0.0003190724,0.7386762,0.0003115332,0.00008134478,0.000004807778,0.00003788315,0.0003142249,0.2529089,0.00008392867,0.00007289393,0.00006581302],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9979053,0.000436782,0.0001011185,0.00009825279,0.001086026,0.0002231727,0.000009176209,0.000003414973,0.0001367625],"genre_scores_gemma":[0.9994009,0.0003970737,0.0000416569,0.000007394578,0.00002299444,0.000006798435,0.00007390006,0.000007501781,0.00004184333],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05684034,"threshold_uncertainty_score":0.3475174,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3135629194","doi":"10.1038/s41408-021-00440-4","title":"Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression","year":2021,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Cancer Institute; National Institutes of Health; Mayo Clinic","keywords":"Immune system; Immunology; Multiple myeloma; Immunosurveillance; Tumor microenvironment; Immunotherapy; Cancer research; Biology; Immunosuppression; Stem cell; Medicine; Cell biology","retraction":null,"screen_n_in":null,"score":{"opus":0.01219157137028142,"gpt":0.2555898192621097,"spread":0.2433982478918283,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000159563,0.0002001454,0.0004004584,0.00008038612,0.000165381,0.00003714647,0.00008679368,0.00008360778,0.0006701334],"category_scores_gemma":[0.00009437727,0.0001492371,0.000144172,0.00009342269,0.00007985606,0.00007657021,0.0001046947,0.000355958,0.000006551217],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007483569,"about_ca_system_score_gemma":0.0002530252,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001811818,"about_ca_topic_score_gemma":0.00003677315,"domain_scores_codex":[0.9983009,0.0001197617,0.0005087461,0.0002608201,0.0004181954,0.0003916363],"domain_scores_gemma":[0.9989477,0.0001182047,0.0002408072,0.0002516411,0.0001141404,0.0003275016],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.0002928869,0.0005303116,0.483336,0.000122285,0.0002802264,0.0009164657,0.00009778605,0.00000171699,0.5098804,3.639859e-7,0.00003963842,0.004501917],"study_design_scores_gemma":[0.007732824,0.000254799,0.5453913,0.0005469645,0.0002057495,0.0008999454,0.0002065745,0.00006543034,0.4443956,0.000004105393,0.0002088083,0.00008786649],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9751148,0.02385271,0.00004266972,0.0003991284,0.0001209639,0.0002191789,0.000154337,0.00001069266,0.00008550807],"genre_scores_gemma":[0.9872159,0.0113593,0.0007044323,0.00003095033,0.00009306135,0.00002448728,0.0000857273,0.00002800778,0.0004580763],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06548475,"threshold_uncertainty_score":0.733749,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3204092402","doi":"10.1038/s41408-021-00555-8","title":"6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy","year":2021,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal","funders":"Genentech; Aptitude Health; AbbVie","keywords":"Medicine; Chemotherapy; Internal medicine; Oncology; Intensive care medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.0115385449882943,"gpt":0.2763887632945106,"spread":0.2648502183062162,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001677522,0.0001705724,0.0004841923,0.0001589183,0.000100146,0.00003035457,0.00007919061,0.00009246368,0.00007548145],"category_scores_gemma":[0.0002439198,0.000124794,0.00007260736,0.0003785695,0.00009366134,0.0001049084,0.00003548668,0.0003731083,3.471125e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001681261,"about_ca_system_score_gemma":0.001210553,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002371683,"about_ca_topic_score_gemma":0.0002628808,"domain_scores_codex":[0.9987398,0.00004088776,0.0003578333,0.0002422119,0.0002497213,0.0003695716],"domain_scores_gemma":[0.997846,0.0001033149,0.0001762013,0.0001619019,0.001525318,0.0001872432],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0127746,0.001200431,0.8967909,0.0002626414,0.001297916,0.0001525489,0.001292342,0.00002403919,0.07090185,0.000009479849,0.001529352,0.01376393],"study_design_scores_gemma":[0.1859392,0.00463375,0.454109,0.001463318,0.0006786829,0.0004238836,0.001214891,0.0006588741,0.3497736,0.00008171214,0.0006305141,0.000392628],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9965754,0.001353434,0.00005122989,0.001236761,0.00007861784,0.0005841429,0.00003178054,0.000009626757,0.00007899428],"genre_scores_gemma":[0.9964891,0.001081698,0.001369863,0.0003793511,0.0001165439,0.00003316555,0.00002394726,0.00003975569,0.0004665777],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4426819,"threshold_uncertainty_score":0.508895,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1974642141","doi":"10.1038/bcj.2012.27","title":"Aberrant expression and biological significance of Sox2, an embryonic stem cell transcriptional factor, in ALK-positive anaplastic large cell lymphoma","year":2012,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Cancer Cells and Metastasis","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"Canadian Cancer Society Research Institute; Killam Trusts; University of Alberta; Alberta Cancer Foundation","keywords":"SOX2; Anaplastic large-cell lymphoma; Biology; Cancer research; Anaplastic lymphoma kinase; Embryonic stem cell; Stem cell; Carcinogenesis; Cell culture; Cancer stem cell; Molecular biology; Cell biology; Lymphoma; Cancer; Immunology; Pathology; Genetics; Medicine; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.02941579013763417,"gpt":0.2718289785923664,"spread":0.2424131884547322,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003236648,0.0002212003,0.0004721631,0.0001425168,0.00009668762,0.000020006,0.00009589837,0.0001312998,0.0003654483],"category_scores_gemma":[0.000004732121,0.0001655317,0.0001275233,0.000157256,0.00007950507,0.0002317036,0.00002279228,0.0003009153,0.000001951122],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001220296,"about_ca_system_score_gemma":0.0002955549,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007076265,"about_ca_topic_score_gemma":0.00005958506,"domain_scores_codex":[0.998307,0.0001515105,0.0004191961,0.0002595216,0.0003378778,0.0005248814],"domain_scores_gemma":[0.999034,0.00006522672,0.0002301013,0.0001345657,0.00009380344,0.000442314],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001128736,0.003187595,0.07781842,0.0002158693,0.0000732671,0.00006167359,0.002354454,0.00001603478,0.9057809,0.00002491324,0.0001337581,0.00920444],"study_design_scores_gemma":[0.02273021,0.001810902,0.4260507,0.0006290846,0.0004250254,0.0004359102,0.001802291,0.00005865826,0.5405561,0.00002173662,0.005044077,0.0004353394],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9689615,0.02943284,0.0003883184,0.00006958571,0.000383064,0.0002425528,0.000221891,0.00001016243,0.0002900623],"genre_scores_gemma":[0.9942727,0.004575131,0.0004101115,0.0001284257,0.0004012187,0.0000231249,0.000009355621,0.00002261643,0.0001572838],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3652247,"threshold_uncertainty_score":0.6750186,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4224221548","doi":"10.1038/s41408-022-00668-8","title":"Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia","year":2022,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Genentech; AbbVie","keywords":"Medicine; Quality of life (healthcare); Internal medicine; Cytarabine; Placebo; Myeloid leukemia; Visual analogue scale; Oncology; Physical therapy","retraction":null,"screen_n_in":null,"score":{"opus":0.008543927453387928,"gpt":0.2656750802293543,"spread":0.2571311527759664,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004315206,0.0001208812,0.0002374675,0.0002648617,0.0002842052,0.00002975402,0.0002767347,0.00003485153,0.001060414],"category_scores_gemma":[0.00003836886,0.00008424003,0.00005536582,0.000732022,0.00005437019,0.0001073247,0.0001327197,0.000741308,0.00001769937],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002319776,"about_ca_system_score_gemma":0.002679831,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001887073,"about_ca_topic_score_gemma":0.00006774978,"domain_scores_codex":[0.9982289,0.0001552459,0.0003452222,0.0001654909,0.0008129886,0.0002921473],"domain_scores_gemma":[0.9990813,0.00005257369,0.0001821266,0.0002347801,0.0003027372,0.0001465181],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01812266,0.00459259,0.5660102,0.0002309786,0.005402052,0.002317759,0.01667786,0.05773838,0.1183285,0.0003719833,0.09399683,0.1162102],"study_design_scores_gemma":[0.06074679,0.01630984,0.8557125,0.0006684293,0.001570733,0.00291536,0.0009698566,0.007243062,0.01072007,0.0004490047,0.04173838,0.0009560197],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9964409,0.0001690752,0.0000613474,0.002121122,0.00007398422,0.0006757152,0.00005898829,0.000009836278,0.0003890363],"genre_scores_gemma":[0.9973413,0.00006004727,0.0004142402,0.0007380261,0.00009758102,0.0002107797,0.00002767872,0.00003190607,0.001078454],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2897022,"threshold_uncertainty_score":0.9998528,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2772253366","doi":"10.1038/s41408-017-0033-8","title":"MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma","year":2017,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"Sigrid Juséliuksen Säätiö; National Cancer Institute; Academy of Finland; Helsingin Yliopisto","keywords":"microRNA; Cancer research; Biology; Diffuse large B-cell lymphoma; Signal transduction; MAPK/ERK pathway; Chemoimmunotherapy; Lymphoma; Cancer; Biological pathway; Immunology; Gene expression; Gene; Cell biology; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.01397823349333842,"gpt":0.2677070162185166,"spread":0.2537287827251782,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002992469,0.0002304174,0.0004893357,0.00006439913,0.0005134884,0.00009770456,0.0001197003,0.0001073919,0.00002950609],"category_scores_gemma":[0.00003237281,0.0001696327,0.0001515303,0.00003562832,0.0001029343,0.0001500805,0.0001425946,0.0001302161,0.000003609754],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001105494,"about_ca_system_score_gemma":0.0002316495,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008919818,"about_ca_topic_score_gemma":0.00003998142,"domain_scores_codex":[0.9985967,0.0000553496,0.0003336383,0.0002709717,0.0003465358,0.0003968415],"domain_scores_gemma":[0.998522,0.00003297388,0.0006129887,0.0004030778,0.0001448705,0.0002840715],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0005802104,0.00979695,0.5757728,0.0005088751,0.0003354965,0.00181721,0.000878908,4.014574e-7,0.3937806,0.000009318546,0.0002179144,0.01630135],"study_design_scores_gemma":[0.03145483,0.0001573848,0.4478002,0.00043266,0.0003284147,0.0003721245,0.00003746769,0.000007175027,0.5190743,0.0000120215,0.0002163672,0.0001070196],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9920946,0.006030757,0.000001253832,0.0004432524,0.0003816544,0.0002145023,0.00005800756,0.0000169563,0.0007589804],"genre_scores_gemma":[0.9942816,0.004819411,0.000203781,0.00003724393,0.0003471852,0.00001359878,0.000004627592,0.00003132611,0.0002612023],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1279725,"threshold_uncertainty_score":0.6917419,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3154921500","doi":"10.1038/s41408-021-00463-x","title":"Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera","year":2021,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Micropharma (Canada); McGill University Health Centre; McGill University; Jewish General Hospital; Hôpital Maisonneuve-Rosemont; Hôpital du Sacré-Cœur de Montréal; Université de Montréal","funders":"","keywords":"Polycythemia vera; Thrombosis; Hematology; Medicine; Internal medicine; Phenotype; Gastroenterology; Immunology; Biology; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.0481629469610597,"gpt":0.3147656740675299,"spread":0.2666027271064702,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001157952,0.0005459551,0.001253626,0.0002325182,0.0001997958,0.0002100359,0.0001354734,0.0006075638,0.00299898],"category_scores_gemma":[0.00006280172,0.0004139511,0.0002480079,0.0002006739,0.0001453552,0.0001162291,0.00008600609,0.003174569,0.000008538802],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003099185,"about_ca_system_score_gemma":0.001087728,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001849981,"about_ca_topic_score_gemma":0.0002644956,"domain_scores_codex":[0.9974985,0.0001704629,0.0005725304,0.0006009354,0.0005774064,0.0005801479],"domain_scores_gemma":[0.9987048,0.0003918042,0.0002694948,0.000251305,0.0001532565,0.000229325],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"observational","study_design_scores_codex":[0.0009816135,0.0008796134,0.3866324,0.0007076393,0.005825399,0.007192076,0.0009747228,7.244623e-7,0.0003443893,0.00002684025,0.5781273,0.01830718],"study_design_scores_gemma":[0.04237162,0.003244043,0.7112461,0.006847692,0.007073366,0.003236165,0.0005922759,0.00001509284,0.01154254,0.0003236907,0.2117949,0.001712432],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.5999117,0.03065636,0.000001893861,0.3666224,0.001272261,0.0003276825,0.0001248637,0.00002149798,0.00106137],"genre_scores_gemma":[0.5082713,0.1056731,0.001278829,0.3625448,0.01982707,0.0006045662,0.0002832536,0.000244918,0.001272075],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3663324,"threshold_uncertainty_score":0.9998313,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4311358889","doi":"10.1038/s41408-022-00765-8","title":"Management of patients with lower-risk myelodysplastic syndromes","year":2022,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"Bristol-Myers Squibb","keywords":"Myelodysplastic syndromes; Medicine; Internal medicine; Disease; Myeloid leukemia; Oncology; Dysplasia; Hematologic disease; International Prognostic Scoring System; Intensive care medicine; Bone marrow","retraction":null,"screen_n_in":null,"score":{"opus":0.03015095816860201,"gpt":0.3252116550783994,"spread":0.2950606969097974,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004405695,0.0004554637,0.001881309,0.0004973589,0.0002012801,0.00003537942,0.0005047264,0.0001372773,0.00514721],"category_scores_gemma":[0.00003919107,0.0003007678,0.0004946423,0.0007335711,0.0001024586,0.00006953256,0.0002737015,0.002182442,0.00002198917],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009806369,"about_ca_system_score_gemma":0.001826809,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002042058,"about_ca_topic_score_gemma":0.000002190219,"domain_scores_codex":[0.9965128,0.0002249322,0.0007419677,0.0004077803,0.001570989,0.0005415854],"domain_scores_gemma":[0.9977927,0.0001276952,0.001051016,0.0005077736,0.0001866276,0.0003341414],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002587398,0.0006889771,0.001421928,0.02725895,0.007772211,0.002753175,0.00002490235,0.000006674117,1.22751e-8,0.00000838728,0.002424502,0.9573815],"study_design_scores_gemma":[0.003884418,0.001679717,0.0006395148,0.02354094,0.01616796,0.001180936,0.00003009846,0.000001510722,2.428058e-7,0.000003918438,0.9525807,0.0002900408],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001255225,0.9958593,0.00001788823,0.00002357109,0.000490142,0.001119008,0.0002374097,0.00001924178,0.0009782418],"genre_scores_gemma":[0.00006986382,0.9968976,0.0004836401,0.00001577854,0.0002698906,0.0002154341,0.00007318055,0.0001288728,0.001845705],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9570915,"threshold_uncertainty_score":0.9999444,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4409147719","doi":"10.1038/s41408-025-01259-z","title":"Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study","year":2025,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University","funders":"Cilag; Pharmacyclics; Genentech; National Institutes of Health; National Cancer Institute; University College London; National Institute for Health and Care Research; Ascentage Pharma; SkylineDx; Regeneron Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Celgene; Swedish Orphan Biovitrum; Array BioPharma; Kite Pharma; Gilead Sciences; BeiGene; Sanofi; Amgen; Bristol-Myers Squibb Foundation; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Multiple myeloma; Refractory (planetary science); Progression-free survival; Dosing; Oncology; Surgery; Gastroenterology; Chemotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.08100113878727644,"gpt":0.4097567351272792,"spread":0.3287555963400027,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001058273,0.0002037304,0.0004173775,0.000403373,0.0002363999,0.00004263131,0.0002511448,0.00005801917,0.0001823985],"category_scores_gemma":[0.0002129329,0.0001310972,0.0002319584,0.0003291208,0.00008368563,0.000144502,0.00003047257,0.0001881651,6.802862e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006985452,"about_ca_system_score_gemma":0.0007359252,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000885081,"about_ca_topic_score_gemma":0.003239773,"domain_scores_codex":[0.9975008,0.0002305283,0.0006405111,0.000283201,0.001055668,0.0002892339],"domain_scores_gemma":[0.9977626,0.0004437215,0.0004070726,0.0004175686,0.0008319652,0.0001370905],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003311236,0.006204061,0.5895035,0.00003398539,0.003296649,0.00002870785,0.0009433347,0.0001018095,0.003220721,0.00005797795,0.00008154528,0.3932165],"study_design_scores_gemma":[0.03883728,0.004177864,0.9391941,0.0003457119,0.002611373,0.00002547057,0.001155518,0.004359676,0.006115372,0.0001140692,0.002953983,0.0001096014],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9934024,0.00231296,0.0001132905,0.0002970374,0.0006704638,0.002210148,0.00005779663,0.0000158794,0.0009200007],"genre_scores_gemma":[0.9956607,0.001938519,0.000708055,0.00002131934,0.0004870058,0.0005446722,0.00003543269,0.00002401771,0.0005802874],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3931069,"threshold_uncertainty_score":0.5345989,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3024544545","doi":"10.1038/s41408-020-0324-3","title":"Staphylococcus aureus enterotoxins induce FOXP3 in neoplastic T cells in Sézary syndrome","year":2020,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre","funders":"LEO Fondet; Kom op tegen Kanker; Kræftens Bekæmpelse; Novo Nordisk Fonden; H. Lundbeck A/S; Lundbeckfonden; Novo Nordisk","keywords":"FOXP3; Immunology; Staphylococcus aureus; Lymphoma; Biology; Immune system; Cancer research; Antigen; MHC class II; T cell","retraction":null,"screen_n_in":null,"score":{"opus":0.02790164722307702,"gpt":0.3006441397954133,"spread":0.2727424925723363,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002356802,0.000239626,0.0005207537,0.0003893453,0.00006903079,0.00006683067,0.0002489348,0.0001263233,0.0009573643],"category_scores_gemma":[0.000185449,0.0002201506,0.0001165001,0.0007329358,0.00007071522,0.0001279843,0.00009054683,0.0012837,0.00005174527],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003412713,"about_ca_system_score_gemma":0.001104328,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000261119,"about_ca_topic_score_gemma":0.000686686,"domain_scores_codex":[0.997633,0.000161015,0.000544788,0.0003617769,0.0006529822,0.0006463716],"domain_scores_gemma":[0.999007,0.0000842312,0.0001144784,0.0001672784,0.0001194513,0.0005075991],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001510692,0.00119521,0.7254556,0.0003407273,0.0002919208,0.02905867,0.004359542,0.0009174807,0.2317186,0.00000736027,0.00229384,0.002850405],"study_design_scores_gemma":[0.09305622,0.01422913,0.6481516,0.005711867,0.000696398,0.03813203,0.006813999,0.00808138,0.1710451,0.0005541514,0.01088007,0.002648042],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924287,0.002385664,0.00004219138,0.003809352,0.0001796342,0.0007184646,0.00002943478,0.00002125974,0.0003852703],"genre_scores_gemma":[0.9968427,0.0008340149,0.000105389,0.001678422,0.0002796693,0.00008153368,0.000003535926,0.00004585135,0.0001289294],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09154552,"threshold_uncertainty_score":0.9999559,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4224245023","doi":"10.1038/s41408-022-00659-9","title":"Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota","year":2022,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute; Mayo Clinic","keywords":"Monoclonal gammopathy of undetermined significance; Internal medicine; Medicine; Hazard ratio; Gastroenterology; Macroglobulinemia; Population; Waldenstrom macroglobulinemia; Body mass index; Proportional hazards model; Univariate analysis; AL amyloidosis; Multiple myeloma; Amyloidosis; Confidence interval; Oncology; Lymphoma; Immunology; Monoclonal; Multivariate analysis; Antibody; Immunoglobulin light chain; Monoclonal antibody","retraction":null,"screen_n_in":null,"score":{"opus":0.01686898181163388,"gpt":0.3038341216571848,"spread":0.2869651398455509,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001070295,0.0002365251,0.0005758103,0.0003479446,0.0001924303,0.0000348685,0.0003442196,0.0001015991,0.0006556546],"category_scores_gemma":[0.0001458906,0.0001922298,0.0001069406,0.0009579359,0.000167292,0.0001315952,0.0001265245,0.001098735,0.00000105403],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.01013123,"about_ca_system_score_gemma":0.01491694,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004961776,"about_ca_topic_score_gemma":0.0002128049,"domain_scores_codex":[0.9961825,0.0002754051,0.0006582011,0.0003595327,0.001884209,0.0006401518],"domain_scores_gemma":[0.9983951,0.0001611215,0.0005424003,0.0003017462,0.0003365724,0.0002630531],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0145532,0.004306335,0.8523486,0.0006809587,0.001557003,0.01358415,0.001364205,0.004236714,0.09663174,0.00005163067,0.002876086,0.007809427],"study_design_scores_gemma":[0.3584721,0.01515907,0.4079693,0.008562436,0.001883255,0.01602012,0.003375228,0.1071459,0.07431646,0.0004689926,0.00450273,0.002124315],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9962503,0.001973775,0.00003016564,0.000404312,0.000183594,0.0006279572,0.00007729957,0.00002622973,0.0004263856],"genre_scores_gemma":[0.9984308,0.0002943497,0.000163829,0.0001111604,0.000188577,0.0002116925,0.0000235913,0.00005456221,0.0005214324],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4443792,"threshold_uncertainty_score":0.9936687,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2017202925","doi":"10.1038/bcj.2015.14","title":"Genetic and epigenetic profiling of CLL disease progression reveals limited somatic evolution and suggests a relationship to memory-cell development","year":2015,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Ontario Institute for Cancer Research","funders":"Ontario Ministry of Research and Innovation; University of California, San Diego; National Cancer Institute; Ontario Genomics; National Institutes of Health; National Center for Advancing Translational Sciences; Ontario Institute for Cancer Research; Government of Canada; Canadian Institutes of Health Research; Ontario Genomics Institute; China Scholarship Council; Genome Canada","keywords":"Epigenetics; DNA methylation; Somatic evolution in cancer; Biology; Chronic lymphocytic leukemia; Tumor progression; Genetics; Somatic cell; Methylation; Leukemia; CpG site; Disease; Cancer research; Cancer; DNA; Medicine; Gene; Pathology; Gene expression","retraction":null,"screen_n_in":null,"score":{"opus":0.03955269313648678,"gpt":0.3295925577553717,"spread":0.2900398646188849,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006200357,0.0001396482,0.0002543725,0.0002196008,0.0001172227,0.00003421729,0.00007385431,0.00006628713,0.00001155501],"category_scores_gemma":[0.0005320694,0.0001130106,0.00002869462,0.0002459349,0.0000698138,0.00006465032,0.00008591769,0.0002113627,0.000003945201],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002100683,"about_ca_system_score_gemma":0.008339125,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000296493,"about_ca_topic_score_gemma":0.00001280102,"domain_scores_codex":[0.9982296,0.00012428,0.0004715784,0.0002299822,0.0006391873,0.0003054278],"domain_scores_gemma":[0.9982796,0.00008574621,0.0001825209,0.0001828162,0.0003258146,0.0009435583],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001042633,0.000459231,0.9605453,0.002145335,0.0001426932,0.000300226,0.003059751,0.0005236822,0.01627,0.00001433147,0.0003544028,0.01514242],"study_design_scores_gemma":[0.02698281,0.0008578274,0.9335361,0.003984991,0.0006724148,0.00133885,0.000501012,0.005033887,0.02601223,0.0006501264,0.00008979454,0.0003399581],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9768153,0.02154225,0.0003999931,0.0003388133,0.000069327,0.0007592602,0.000002829782,0.00001414669,0.00005800902],"genre_scores_gemma":[0.9816577,0.0002425838,0.01761185,0.00003997335,0.000157254,0.00007381268,0.000002551298,0.00002364808,0.0001906361],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02700919,"threshold_uncertainty_score":0.9972827,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3216448276","doi":"10.1038/s41408-021-00569-2","title":"Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis","year":2021,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute","keywords":"Multiple myeloma; Risk stratification; Medicine; Stratification (seeds); Internal medicine; Oncology; Intensive care medicine; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.04377945206950377,"gpt":0.3397416861487298,"spread":0.295962234079226,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004400234,0.0001504034,0.0002782915,0.00006078171,0.0003570923,0.0001934476,0.0001266332,0.00006119163,0.0005240447],"category_scores_gemma":[0.0009731088,0.0001007967,0.0001258279,0.0002400388,0.00009629613,0.0001602338,0.00004995651,0.0004116236,0.000004063952],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005279608,"about_ca_system_score_gemma":0.0009537202,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002618844,"about_ca_topic_score_gemma":0.0003643244,"domain_scores_codex":[0.9983116,0.0001841731,0.0004188584,0.0002400254,0.0005344247,0.0003108637],"domain_scores_gemma":[0.9982791,0.0003822901,0.0003082115,0.0003063305,0.0005263981,0.0001976512],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001615317,0.0005507601,0.8711827,0.0001118276,0.0005342002,0.0001321517,0.0002599772,0.00002394633,0.04292226,0.000009552728,0.0000590966,0.08405202],"study_design_scores_gemma":[0.002656758,0.0001018179,0.8588909,0.0002636462,0.0004309007,0.0001834426,0.0005116477,0.0003358012,0.1364191,0.00006859662,0.00006229543,0.00007516524],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.995727,0.002333852,0.000223126,0.0006316091,0.0001520058,0.0004605109,0.00005194127,0.00001844112,0.0004014859],"genre_scores_gemma":[0.9965792,0.001105988,0.001732216,0.0000451969,0.0003214645,0.0001401921,0.00002918622,0.00002050784,0.00002601205],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0934968,"threshold_uncertainty_score":0.5737922,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2559984635","doi":"10.1038/bcj.2016.110","title":"MiR-139-5p is a potent tumor suppressor in adult acute myeloid leukemia","year":2016,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Deutsche Krebshilfe; Medizinische Fakultät, Universität Ulm; Canadian Institutes of Health Research; Universität Ulm; European Hematology Association; Barncancerfonden; Cancerfonden; Deutsche Forschungsgemeinschaft; Västra Götalandsregionen","keywords":"Myeloid leukemia; Medicine; Leukemia; Cancer research; Hematology; Myeloid; Suppressor; Oncology; Immunology; Internal medicine; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.01615550641676555,"gpt":0.2928319220175375,"spread":0.276676415600772,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0006979853,0.001053065,0.00183005,0.001221657,0.0002477204,0.000232588,0.001274089,0.001349274,0.004424353],"category_scores_gemma":[0.0002163198,0.0007529843,0.0008059432,0.0005670948,0.0003036628,0.0003253589,0.0003627499,0.01166938,0.0004520127],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.005593727,"about_ca_system_score_gemma":0.008230497,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008421041,"about_ca_topic_score_gemma":0.00007668154,"domain_scores_codex":[0.9918755,0.0003461476,0.001466133,0.001174867,0.002667522,0.002469826],"domain_scores_gemma":[0.9959783,0.0002058448,0.0008084032,0.001218058,0.00103868,0.0007507165],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0006819934,0.00009542701,0.0007161382,0.0004467528,0.001863421,0.04398652,0.0003226505,0.000001217596,0.006979983,0.000002052554,0.9403301,0.00457369],"study_design_scores_gemma":[0.01670916,0.000749825,0.0008970439,0.004699199,0.001828686,0.02238477,0.0000489171,0.00004962283,0.01560569,0.0001206283,0.9358877,0.001018734],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.0413289,0.004134185,0.00003677949,0.947373,0.001739741,0.00133567,0.001021817,0.000100595,0.002929359],"genre_scores_gemma":[0.001737743,0.009691426,0.001167846,0.9047121,0.03983,0.0004958917,0.0001395569,0.0005149921,0.04171041],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.04266082,"threshold_uncertainty_score":0.9999472,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4362614405","doi":"10.1038/s41408-023-00820-y","title":"Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma","year":2023,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Multiple myeloma; Bone marrow; Internal medicine; Minimal residual disease; Gastroenterology","retraction":null,"screen_n_in":null,"score":{"opus":0.03690454814867489,"gpt":0.3457851510166651,"spread":0.3088806028679902,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008148252,0.0001590743,0.0004349918,0.0004360216,0.00007127754,0.00003705046,0.0001411761,0.0000958839,0.000910697],"category_scores_gemma":[0.0001420238,0.0001327892,0.0001930382,0.000715657,0.0000768262,0.00007838439,0.0000291548,0.000483062,0.00000788551],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001426784,"about_ca_system_score_gemma":0.0009496724,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000397383,"about_ca_topic_score_gemma":0.0001112311,"domain_scores_codex":[0.9978839,0.00009518833,0.0004560862,0.0002201571,0.0006498483,0.0006948811],"domain_scores_gemma":[0.9988742,0.0002066888,0.000149239,0.000221295,0.0002865626,0.0002620032],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003351037,0.0003809493,0.4944769,0.0001997637,0.0005103154,0.0003886299,0.001827561,0.00007735031,0.3705435,0.00005035752,0.002267434,0.1259262],"study_design_scores_gemma":[0.02098801,0.003912775,0.8950074,0.0006868432,0.0001783562,0.0003755989,0.0004164707,0.0003092077,0.06119845,0.0007370191,0.01591519,0.0002747022],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9915948,0.005541678,0.00001658907,0.001188751,0.0002898111,0.0009711892,0.00004224745,0.00003294673,0.0003219866],"genre_scores_gemma":[0.9868065,0.008351543,0.0003424587,0.0001517037,0.0007543722,0.0002156518,0.000009626798,0.0000720672,0.003296088],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4005305,"threshold_uncertainty_score":0.9971494,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4323316666","doi":"10.1038/s41408-023-00794-x","title":"Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients","year":2023,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Medicine; Minimal residual disease; Oncology; Positron emission tomography; Internal medicine; Negativity effect; Multiple myeloma; Nuclear medicine; Bone marrow","retraction":null,"screen_n_in":null,"score":{"opus":0.06746045659604068,"gpt":0.3227898492235833,"spread":0.2553293926275427,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002321761,0.0001287167,0.0003330978,0.0008558999,0.0000879535,0.00004385487,0.00005796149,0.00003113658,0.0001221008],"category_scores_gemma":[0.00007515523,0.00009957818,0.00009468517,0.00108753,0.00004303112,0.0001334694,0.00001594582,0.0002010153,0.000001868795],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001620663,"about_ca_system_score_gemma":0.0005452043,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009922031,"about_ca_topic_score_gemma":0.001732971,"domain_scores_codex":[0.9985669,0.00009393629,0.000369122,0.0002058229,0.000459475,0.0003046943],"domain_scores_gemma":[0.9992288,0.00003600304,0.0001024005,0.0001122099,0.0001678726,0.0003526538],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0007927588,0.000184917,0.9686492,0.00005997106,0.00129031,0.001064109,0.0005386733,0.0002845363,0.01808738,0.00000271191,0.0001876557,0.008857792],"study_design_scores_gemma":[0.004869115,0.0002810815,0.970279,0.0002444084,0.001648775,0.00003370436,0.000197407,0.01782667,0.004498498,0.00000784436,0.00001953971,0.0000939489],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.998437,0.0007977542,0.000006992328,0.0002433738,0.00004914901,0.0001887676,0.0002282933,0.00001318912,0.00003548816],"genre_scores_gemma":[0.9970877,0.002128558,0.0001882843,0.00003405887,0.0001059157,0.00002470856,0.0003315683,0.00001323778,0.00008592576],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01754213,"threshold_uncertainty_score":0.406068,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2791331105","doi":"10.1038/s41408-017-0039-2","title":"Del11q-positive CLL lymphocytes exhibit altered glutamine metabolism and differential response to GLS1 and glucose metabolism inhibition","year":2018,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; Jewish General Hospital","funders":"Faculty of Medicine, McGill University; McGill University","keywords":"Metabolism; Glutamine; Carbohydrate metabolism; Biology; Biochemistry; Medicine; Amino acid","retraction":null,"screen_n_in":null,"score":{"opus":0.01505442161798423,"gpt":0.28737974831661,"spread":0.2723253266986257,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0009822675,0.0009496381,0.001728879,0.001059636,0.000462477,0.0005009162,0.0003030439,0.001025456,0.0005826434],"category_scores_gemma":[0.0004870629,0.0007877455,0.0003243966,0.0004510577,0.0005619869,0.0003130394,0.0005225249,0.002528652,0.00004051771],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.005105082,"about_ca_system_score_gemma":0.008172868,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007469886,"about_ca_topic_score_gemma":0.00005533587,"domain_scores_codex":[0.9937866,0.0007845764,0.001053534,0.001186122,0.001778454,0.001410724],"domain_scores_gemma":[0.9964105,0.0004680833,0.0005285391,0.0006749287,0.0008812897,0.00103665],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.033372,0.0005589557,0.0001301747,0.001478136,0.006067636,0.01661478,0.00373851,0.000004942125,0.171636,0.0000207714,0.7437168,0.02266129],"study_design_scores_gemma":[0.1263786,0.00237247,0.008280672,0.005249745,0.01013495,0.05415894,0.0002105072,0.0004908873,0.2149172,0.0003360433,0.5751942,0.002275735],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8590387,0.03020581,0.0001558457,0.1075384,0.001322047,0.001114164,0.0004857566,0.00006366654,0.00007566806],"genre_scores_gemma":[0.4478974,0.03185821,0.00254415,0.39797,0.1109021,0.0006100026,0.0005293732,0.0008816091,0.006807233],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4111413,"threshold_uncertainty_score":0.9997725,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1964507957","doi":"10.1038/bcj.2014.75","title":"Hypermethylation of the tumor suppressor gene PRDM1/Blimp-1 supports a pathogenetic role in EBV-positive Burkitt lymphoma","year":2014,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Saskatchewan","funders":"Weill Cornell Medical College","keywords":"Lymphoma; Suppressor; Burkitt's lymphoma; Cancer research; Tumor suppressor gene; Gene; DNA methylation; Medicine; Biology; Immunology; Carcinogenesis; Genetics; Gene expression","retraction":null,"screen_n_in":null,"score":{"opus":0.00527948037420535,"gpt":0.2322843811872448,"spread":0.2270049008130394,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004138782,0.0001767508,0.0003812036,0.0001347855,0.0001175586,0.00002750755,0.0001560074,0.00009771399,0.0001734449],"category_scores_gemma":[0.0001159694,0.0001283008,0.000194853,0.0003305092,0.00007293699,0.0000867483,0.00004060817,0.0002435475,0.000002137373],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001868746,"about_ca_system_score_gemma":0.0005932666,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003758228,"about_ca_topic_score_gemma":0.0002024755,"domain_scores_codex":[0.998288,0.0001799491,0.0004701641,0.0002153971,0.0004721805,0.0003743329],"domain_scores_gemma":[0.9989904,0.00004012734,0.0004066893,0.0002306599,0.0001843648,0.0001477873],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0007873401,0.0009467378,0.5205089,0.0001056734,0.0004119445,0.0001142841,0.002469781,0.0009550774,0.4238452,0.00005444151,0.001060007,0.04874059],"study_design_scores_gemma":[0.01216679,0.0006415799,0.803391,0.0004471997,0.0006346806,0.0005303652,0.0004913555,0.0005659725,0.1789422,0.0008370462,0.001105982,0.0002457829],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9930273,0.004113139,0.00003184046,0.000874339,0.000330962,0.000310233,0.00003932224,0.00001073642,0.001262154],"genre_scores_gemma":[0.9982186,0.0003868429,0.0001354281,0.0007162552,0.0003322588,0.00003467615,0.000006503457,0.0000315483,0.0001378747],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2828821,"threshold_uncertainty_score":0.5231956,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4400428906","doi":"10.1038/s41408-024-01084-w","title":"Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission","year":2024,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Institute of Environmental Health Sciences; National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Pharmacyclics; Takeda Oncology; Health Resources and Services Administration; MorphoSys; Swedish Orphan Biovitrum; Vertex Pharmaceuticals; Omeros Corporation; Astellas Pharma; Adaptive Biotechnologies; Pfizer; Incyte; Kiadis Pharma; bluebird bio; Jazz Pharmaceuticals; StemCyte; Actinium Pharmaceuticals; CareDx; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; Bristol-Myers Squibb; CSL Behring; BeiGene; HistoGenetics; Atara Biotherapeutics; National Cancer Institute; Gilead Sciences; Sanofi; GlaxoSmithKline; Gateway for Cancer Research; Mallinckrodt Pharmaceuticals; Astellas Pharma US; Amgen","keywords":"Medicine; Cumulative incidence; Internal medicine; Univariate analysis; Incidence (geometry); Progression-free survival; Hematopoietic cell; Surgery; Retrospective cohort study; Hematopoietic stem cell transplantation; Transplantation; Multivariate analysis; Chemotherapy; Haematopoiesis","retraction":null,"screen_n_in":null,"score":{"opus":0.02750997811990137,"gpt":0.2966512924150291,"spread":0.2691413142951278,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003055788,0.0001902197,0.0003863756,0.0003940751,0.0000559812,0.00006026892,0.0001231486,0.0001028502,0.002159376],"category_scores_gemma":[0.000005779332,0.0001258985,0.0000816396,0.0005488389,0.00005178665,0.00008993215,0.000009601227,0.0009242599,0.000006373033],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003144313,"about_ca_system_score_gemma":0.0004488724,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006733788,"about_ca_topic_score_gemma":0.0004365526,"domain_scores_codex":[0.998252,0.0001231893,0.0003472503,0.000280058,0.0005547003,0.0004428292],"domain_scores_gemma":[0.9994379,0.00004958126,0.00004686544,0.0001713929,0.00009351427,0.0002007131],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0055346,0.0007314117,0.8858428,0.00009325616,0.0002718301,0.002047999,0.001577783,0.00004170498,0.0225972,0.000003189693,0.0005613597,0.08069688],"study_design_scores_gemma":[0.02634117,0.003000429,0.9447457,0.002796919,0.0001058616,0.0006942879,0.00005412388,0.0004523795,0.006482588,0.00002624183,0.01502863,0.0002716838],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9936263,0.003977149,0.000005035023,0.000948158,0.0001610455,0.0004495466,0.00003589581,0.00004009238,0.0007567614],"genre_scores_gemma":[0.9957082,0.00308349,0.00005063312,0.0001745732,0.0001876964,0.00003080897,0.00002490517,0.0000488982,0.0006908324],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0804252,"threshold_uncertainty_score":0.9987528,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W344822596","doi":"10.1038/bcj.2015.35","title":"NPM-ALK mediates phosphorylation of MSH2 at tyrosine 238, creating a functional deficiency in MSH2 and the loss of mismatch repair","year":2015,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"Alberta Innovates; Killam Trusts; University of Alberta; Alberta Cancer Foundation","keywords":"Anaplastic lymphoma kinase; MSH2; Cancer research; Phosphorylation; Tyrosine kinase; Tyrosine phosphorylation; Anaplastic large-cell lymphoma; Transfection; Tyrosine; Molecular biology; Chemistry; Biology; Cell biology; Signal transduction; DNA mismatch repair; Biochemistry; DNA repair; Lymphoma; Medicine; DNA; Gene; Internal medicine; Immunology","retraction":null,"screen_n_in":null,"score":{"opus":0.02401015922207992,"gpt":0.2674418269540381,"spread":0.2434316677319582,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009748715,0.0001314354,0.0003672348,0.0001017565,0.00007227183,0.000009350768,0.00007940755,0.00008107067,0.0002173804],"category_scores_gemma":[0.0004543823,0.00008771355,0.00009721961,0.000272686,0.0002754648,0.00005863321,0.00006084738,0.0002662624,9.054069e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001960267,"about_ca_system_score_gemma":0.0005333668,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004050866,"about_ca_topic_score_gemma":0.0002954557,"domain_scores_codex":[0.9983652,0.0000863963,0.0005689327,0.000168089,0.0006119869,0.0001994207],"domain_scores_gemma":[0.9987405,0.000197109,0.0003920861,0.0001511567,0.0003919588,0.0001271676],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00278943,0.0002004627,0.9763733,0.0001703316,0.0001350419,0.00001798058,0.004164847,0.001155978,0.01225184,0.00008061095,0.00139126,0.001268918],"study_design_scores_gemma":[0.03090967,0.001553416,0.8439566,0.001204639,0.0009428691,0.001664731,0.002124899,0.002476298,0.11234,0.001687585,0.0008034051,0.000335829],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9719725,0.02564793,0.00003759583,0.0006120706,0.0004113595,0.0002225034,0.00001011312,0.00001035993,0.001075568],"genre_scores_gemma":[0.9976466,0.0009782006,0.0008146247,0.00009425024,0.0002492186,0.00001837375,0.000002796679,0.00001585941,0.0001801188],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1324167,"threshold_uncertainty_score":0.3576855,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4312114026","doi":"10.1038/s41408-022-00760-z","title":"Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia","year":2022,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Kingston Health Sciences Centre; University of Manitoba; CancerCare Manitoba","funders":"Cilag; Pharmacyclics; Kite Pharma; Canadian Institutes of Health Research; Ipsen; MorphoSys; Associazione Italiana per la Ricerca sul Cancro; Aptitude Health; Cancer Research UK; Ascentage Pharma; BeiGene; Celltrion; Hairy Cell Leukemia Foundation; Adaptive Biotechnologies; Astex Pharmaceuticals; TG Therapeutics; Genentech; Blood Cancer UK; Amicus Therapeutics; Incyte; Pfizer; Biogen; University of Rochester; CancerCare Manitoba Foundation; MEI Pharma; Daiichi-Sankyo; MacroGenics; Sunesis; University of Pittsburgh; National Cancer Institute; Servier; Gilead Sciences; Teva Pharmaceutical Industries; Leukemia and Lymphoma Society; Sanofi; Ipsen Biopharmaceuticals; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; National Institutes of Health; Leukemia and Lymphoma Society of Canada; GlaxoSmithKline","keywords":"Minimal residual disease; Oncology; Medicine; Bone marrow; Internal medicine; Leukemia; Flow cytometry; Hematology; Hairy cell leukemia; Disease; Cancer research; Immunology","retraction":null,"screen_n_in":null,"score":{"opus":0.100051708671966,"gpt":0.4030415436695617,"spread":0.3029898349975957,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007997653,0.0004267839,0.001453653,0.0006107761,0.0001106012,0.00005855854,0.0006621773,0.0002232799,0.002960842],"category_scores_gemma":[0.0002964794,0.000356788,0.0004458665,0.0003184224,0.0001150782,0.0001036054,0.0001869094,0.001508115,0.000008642129],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.02682804,"about_ca_system_score_gemma":0.04025908,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003605387,"about_ca_topic_score_gemma":0.0001175252,"domain_scores_codex":[0.9952279,0.0006159568,0.001168698,0.0006108104,0.001882778,0.0004938127],"domain_scores_gemma":[0.9974758,0.0004579244,0.0006848245,0.0006468394,0.000134169,0.0006004308],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.003777034,0.002607102,0.0008907922,0.01301445,0.001889317,0.009071021,0.0006882688,0.000434878,0.0000314024,0.00005226619,0.01416187,0.9533816],"study_design_scores_gemma":[0.01904467,0.0005708353,0.0001391697,0.02433733,0.0009616673,0.0008032371,0.0001384932,0.000312048,0.00002759673,0.00004276256,0.9531859,0.0004363258],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.006653881,0.9892236,0.000001273524,0.0001011568,0.001781214,0.0006475861,0.0004413215,0.00002000163,0.00112995],"genre_scores_gemma":[0.001048894,0.9955352,0.000133795,0.0001075415,0.002181374,0.000178646,0.0004002547,0.0001035209,0.0003107775],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9529453,"threshold_uncertainty_score":0.9998884,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3206224016","doi":"10.1038/s41408-021-00561-w","title":"Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants","year":2021,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":23,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Associazione Italiana per la Ricerca sul Cancro","keywords":"Acute promyelocytic leukemia; NPM1; Retinoic acid receptor alpha; Myeloid leukemia; Retinoic acid; Cancer research; Retinoic acid receptor; Leukemia; Myeloid; Hematology; Medicine; Arsenic trioxide; Internal medicine; Biology; Oncology; Immunology; Genetics; Karyotype","retraction":null,"screen_n_in":null,"score":{"opus":0.01054446335079227,"gpt":0.2419341986136415,"spread":0.2313897352628492,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002831515,0.0005294448,0.0007627353,0.00009771719,0.0001905517,0.000134149,0.0004885444,0.001049661,0.0001804056],"category_scores_gemma":[0.00005152704,0.0004337092,0.0001968844,0.000127821,0.0002000368,0.00001277958,0.0002304176,0.001819364,0.000001940082],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009691717,"about_ca_system_score_gemma":0.001128032,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002292479,"about_ca_topic_score_gemma":0.000009357409,"domain_scores_codex":[0.9974091,0.0001846163,0.0007484141,0.0006262691,0.0005323855,0.0004992384],"domain_scores_gemma":[0.9978424,0.00001979662,0.001016273,0.0005271701,0.0004489327,0.00014545],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0004340107,0.00008105632,0.04584363,0.001254965,0.002322737,0.001491558,0.0001356267,0.000003531555,0.7310823,0.000002180913,0.2126831,0.004665361],"study_design_scores_gemma":[0.002721973,0.001095122,0.00334324,0.001157864,0.002009978,0.003802225,0.00004388246,0.000004099546,0.6081906,0.00002377741,0.3765114,0.001095819],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9617169,0.01799731,0.0004033981,0.01696125,0.001549686,0.000274655,0.0004860114,0.0000188488,0.0005919078],"genre_scores_gemma":[0.5233681,0.2250409,0.008616763,0.1758211,0.04143274,0.0001926257,0.005933722,0.0008685762,0.01872555],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4383488,"threshold_uncertainty_score":0.9998115,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2019849294","doi":"10.1038/bcj.2013.50","title":"Synergistic apoptotic response between valproic acid and fludarabine in chronic lymphocytic leukaemia (CLL) cells involves the lysosomal protease cathepsin B","year":2013,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"Canadian Institutes of Health Research; Leukemia and Lymphoma Society of Canada; CancerCare Manitoba Foundation; Leukemia and Lymphoma Society","keywords":"Fludarabine; Cathepsin B; Chronic lymphocytic leukemia; Cancer research; Vorinostat; Cathepsin; Apoptosis; Histone deacetylase; Medicine; Immunology; Chemistry; Leukemia; Histone; Internal medicine; Chemotherapy; Biochemistry","retraction":null,"screen_n_in":null,"score":{"opus":0.02109960693894923,"gpt":0.2900111483050746,"spread":0.2689115413661254,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001632741,0.0004436183,0.0007247436,0.0004001621,0.0003437967,0.000256163,0.0005024671,0.000227955,0.0005315512],"category_scores_gemma":[0.0006026759,0.0002981931,0.0001739024,0.0006508479,0.0005421061,0.0002928218,0.0002217896,0.001184162,0.0001199511],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.03576741,"about_ca_system_score_gemma":0.04021239,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003987858,"about_ca_topic_score_gemma":0.0001851119,"domain_scores_codex":[0.9957845,0.0006187287,0.0008644518,0.0005620683,0.001008926,0.001161295],"domain_scores_gemma":[0.9974445,0.0005778791,0.0002855468,0.000699595,0.0002644515,0.0007281008],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.004940436,0.0004910094,0.02107988,0.002225042,0.001580711,0.003219551,0.003625618,0.001757988,0.9324806,0.00006616017,0.004547227,0.02398573],"study_design_scores_gemma":[0.1723211,0.005653735,0.1317384,0.007205958,0.003335799,0.01045864,0.001346665,0.03730498,0.6237018,0.002019094,0.002626974,0.002286926],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9830437,0.01320637,0.0000425075,0.001716821,0.0001874528,0.001663885,0.00001505977,0.00004415351,0.0000800228],"genre_scores_gemma":[0.995405,0.001200058,0.0002340685,0.0002793295,0.001345626,0.0003850474,0.000004824001,0.00008926296,0.001056797],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3087789,"threshold_uncertainty_score":0.999947,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4386441220","doi":"10.1038/s41408-023-00905-8","title":"Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database","year":2023,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Jewish General Hospital; Memorial University of Newfoundland; Saint John Regional Hospital; McGill University; McGill University Health Centre; Queen Elizabeth II Health Sciences Centre; Dalhousie University; Princess Margaret Cancer Centre; University of Calgary; Vancouver General Hospital; University of British Columbia; Institute of Cancer Research; CancerCare Manitoba; Ottawa Hospital; London Health Sciences Centre; McMaster University; Western University; Hôpital Maisonneuve-Rosemont; Université Laval","funders":"","keywords":"Multiple myeloma; Medicine; Transplantation; Stem cell; Autologous stem-cell transplantation; Oncology; Internal medicine; Biology; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.07226150521320708,"gpt":0.361496175435274,"spread":0.2892346702220669,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002494816,0.000217712,0.0004349425,0.0008977476,0.0004685123,0.00007993732,0.0003462567,0.0001244696,0.0000911001],"category_scores_gemma":[0.0003604239,0.0001564806,0.0001264015,0.001620218,0.0001702753,0.0001673603,0.00005379918,0.00114359,0.00003281016],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000621067,"about_ca_system_score_gemma":0.002778743,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.7319516,"about_ca_topic_score_gemma":0.9515372,"domain_scores_codex":[0.9957677,0.0005794601,0.0008742921,0.0004809664,0.001320504,0.0009770717],"domain_scores_gemma":[0.9968132,0.001217263,0.0002603567,0.0006280871,0.0003628975,0.0007182022],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004688025,0.0005209445,0.8375113,0.0001792398,0.0004314811,0.09630194,0.003717097,0.00009068711,0.009278611,0.0000144294,0.01426989,0.03299635],"study_design_scores_gemma":[0.01587738,0.0002687948,0.9706919,0.0006558993,0.0001531104,0.0005185917,0.0007598256,0.0004583392,0.008594894,0.0000410356,0.001838011,0.0001422067],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9913163,0.0008417762,0.000004341442,0.003338715,0.0002492122,0.0009214923,0.00148836,0.00003889621,0.001800901],"genre_scores_gemma":[0.9931028,0.003981452,0.0003699687,0.00005504863,0.000407916,0.0001629691,0.0008533141,0.00004269097,0.001023771],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2195856,"threshold_uncertainty_score":0.6381094,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}